<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>KAZANO- alogliptin benzoate and metformin hydrochloride tablet, film coated </strong><br>Takeda Pharmaceuticals America, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use KAZANO safely and effectively. See full prescribing information for KAZANO.<br><br>KAZANO (alogliptin and metformin HCl) tablets for oral administration<br>Initial U.S. Approval: 2013</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span></h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning</span></h1>
<dl>
<dt>•</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> can occur due to metformin accumulation. The risk increases with conditions such as <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, excess alcohol intake, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and acute <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. (<a href="#S5.1">5.1</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">Symptoms include <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, increasing <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and nonspecific <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal distress</span>. Laboratory abnormalities include low pH, increased <span class="product-label-link" type="condition" conceptid="4009397" conceptname="Anion gap">anion gap</span> and elevated blood lactate. (<a href="#S5.1">5.1</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">If <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> is suspected, discontinue KAZANO and hospitalize the patient immediately. (<a href="#S5.1">5.1</a>)</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta"> </p>
<p class="Highlighta">Warnings and Precautions (<a href="#ID_af7abe64-3252-4f5c-87bb-1ab5210cee41">5.10</a>)                                           8/2015 </p>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span></h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning</span></h1>
<dl>
<dt>•</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> can occur due to metformin accumulation. The risk increases with conditions such as <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, excess alcohol intake, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and acute <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. (<a href="#S5.1">5.1</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">Symptoms include <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, increasing <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and nonspecific <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal distress</span>. Laboratory abnormalities include low pH, increased <span class="product-label-link" type="condition" conceptid="4009397" conceptname="Anion gap">anion gap</span> and elevated blood lactate. (<a href="#S5.1">5.1</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">If <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> is suspected, discontinue KAZANO and hospitalize the patient immediately. (<a href="#S5.1">5.1</a>)</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">KAZANO is a dipeptidyl-peptidase-4 (DPP-4) inhibitor and a biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. (<a href="#S1.1">1.1</a>) </p>
<p class="Highlighta">Important Limitation of Use: Not for treatment of type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>. (<a href="#S1.2">1.2</a>) </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>Individualize the starting dose of KAZANO based on the patient's current regimen. (<a href="#S2.1">2.1</a>)</dd>
<dt>•</dt>
<dd>KAZANO should be taken twice daily with food. (<a href="#S2.1">2.1</a>)</dd>
<dt>•</dt>
<dd>May adjust the dosing based on effectiveness and tolerability while not exceeding the maximum recommended daily dose of 25 mg alogliptin and 2000 mg metformin HCl. (<a href="#S2.1">2.1</a>)</dd>
</dl></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 12.5 mg alogliptin and 500 mg metformin HCl, 12.5 mg alogliptin and 1000 mg metformin HCl. (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>. (<a href="#S4">4</a>,<a href="#S5.2"> 5.5</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic acidosis</span>, including <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>. (<a href="#S4">4</a>,<a href="#S5.1"> 5.1</a>)</dd>
<dt>•</dt>
<dd>History of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to alogliptin or metformin, components of KAZANO, such as <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> or severe cutaneous adverse reactions. (<a href="#S4">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span>: Warn against excessive alcohol intake. KAZANO is not recommended in <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and is contraindicated in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Ensure normal renal function before initiating and at least annually thereafter. (<a href="#S5.1">5.1</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">Acute pancreatitis</span>: There have been postmarketing reports of <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span>. If <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> is suspected, promptly discontinue KAZANO. (<a href="#ID_0135a0a5-9eff-4ab4-875c-0261656cbd9d">5.2</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>: There have been postmarketing reports of serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> in patients treated with alogliptin such as <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and severe cutaneous adverse reactions. In such cases, promptly discontinue KAZANO, assess for other potential causes, institute appropriate monitoring and treatment and initiate alternative treatment for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. (<a href="#ID_8da8d384-567b-4837-abe1-da6393cabc7d">5.3</a>)</dd>
<dt>•</dt>
<dd>Hepatic effects: Postmarketing reports of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, sometimes fatal. Causality cannot be excluded. If <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> is detected, promptly interrupt KAZANO and assess patient for probable cause, then treat cause if possible, to resolution or stabilization. Do not restart KAZANO if <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> is confirmed and no alternative etiology can be found. (<a href="#ID_8eeca7bc-a1cf-47cc-ac53-198328eb8b21">5.4</a>)</dd>
<dt>•</dt>
<dd>Temporarily discontinue in patients undergoing radiologic studies with intravascular administration of iodinated contrast materials or any surgical procedures necessitating restricted intake of food and fluids. (<a href="#S5.2">5.5</a>)</dd>
<dt>•</dt>
<dd>Vitamin B<span class="Sub">12</span> deficiency: Metformin may lower vitamin B<span class="Sub">12</span> levels. Monitor hematologic parameters annually. (<a href="#S5.6">5.8</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span>: When used with an insulin secretagogue (e.g., sulfonylurea) or with insulin, a lower dose of the insulin secretagogue or insulin may be required to reduce the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. (<a href="#S5.7">5.9</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>: Severe and disabling <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> has been reported in patients taking DPP-4 inhibitors. Consider as a possible cause for severe <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span> and discontinue drug if appropriate. (<a href="#ID_af7abe64-3252-4f5c-87bb-1ab5210cee41">5.10</a>)</dd>
<dt>•</dt>
<dd>Macrovascular outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with KAZANO or any other antidiabetic drug. (<a href="#S5.8">5.11</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Common adverse reactions reported in ≥4% of patients treated with coadministration of alogliptin with metformin were: <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>. (<a href="#S6.1">6.1</a>)<br>  </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals at 1-877-TAKEDA-7 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Cationic drugs eliminated by renal tubular secretion: Use with caution. (<a href="#S7.2">7.2</a>) </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Pregnancy Category B: There are no adequate and well-controlled studies in pregnant women. (<a href="#S8.1">8.1</a>)</dd>
<dt>•</dt>
<dd>Pediatrics: Safety and effectiveness of KAZANO in patients below the age of 18 have not been established. (<a href="#S8.4">8.4</a>)</dd>
<dt>•</dt>
<dd>Geriatric Use: Caution should be used when prescribing KAZANO to elderly patients because reduced renal functions are associated with increasing age. (<a href="#S8.5">8.5</a>)</dd>
</dl></div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div><div><div></div></div></div>
</div>
<div></div>
</div>
</div>
<div><div><div></div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 8/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span></a></h1>
<h1><a href="#section-1" class="toc">1	INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1	Monotherapy and Combination Therapy</a></h2>
<h2><a href="#section-1.2" class="toc">1.2	Limitation of Use</a></h2>
<h1><a href="#section-2" class="toc">2	DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Recommendations for All Patients</a></h2>
<h1><a href="#section-3" class="toc">3	DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4	CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5	WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	<span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Hepatic Effects</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Monitoring of Renal Function</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">Hypoxic</span> States</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Alcohol Intake</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Vitamin B12 Levels</a></h2>
<h2><a href="#section-5.9" class="toc">5.9	Use with Medications Known to Cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></a></h2>
<h2><a href="#section-5.10" class="toc"><span class="XmChange">5.10 Severe and Disabling <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Macrovascular Outcomes</a></h2>
<h1><a href="#section-6" class="toc">6	ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Laboratory Abnormalities</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7	DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.2" class="toc">7.1	Carbonic Anhydrase Inhibitors </a></h2>
<h2><a href="#section-7.3" class="toc">7.2	Cationic Drugs</a></h2>
<h2><a href="#section-7.4" class="toc">7.3	The Use of Metformin with Other Drugs</a></h2>
<h1><a href="#section-8" class="toc">8	USE IN SPECIFIC POPULATIONS </a></h1>
<h2><a href="#section-8.1" class="toc">8.1	Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3	Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4	Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5	Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10	OVERDOSAGE </a></h1>
<h1><a href="#section-10" class="toc">11 	DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12	CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1	Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2	Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3	Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13	NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14	CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17	PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1	Instructions</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1>WARNING: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span></h1>
<dl>
<dt>•</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> is a rare but serious complication that can occur due to metformin accumulation. The risk increases with conditions such as <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, excess alcohol intake, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and acute <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>].</span></span></dd>
<dt>•</dt>
<dd><span class="Bold">The onset is often subtle, accompanied only by nonspecific symptoms such as <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, increasing <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and nonspecific <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal distress</span>. Laboratory abnormalities include low pH, increased <span class="product-label-link" type="condition" conceptid="4009397" conceptname="Anion gap">anion gap</span> and elevated blood lactate <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>].</span></span></dd>
<dt>•</dt>
<dd><span class="Bold">If <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> is suspected, KAZANO (alogliptin and metformin HCl) should be discontinued and the patient hospitalized immediately<span class="Italics"> [see <a href="#S5.1">Warnings and Precautions (5.1)</a>].</span></span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1	INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1	Monotherapy and Combination Therapy</h2>
<p class="First">KAZANO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus in multiple clinical settings when treatment with both alogliptin and metformin is appropriate <span class="Italics">[see<a href="#S14"> Clinical Studies (14)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2	Limitation of Use</h2>
<p class="First">KAZANO should not be used in patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or for the treatment of <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>, as it would not be effective in these settings.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2	DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Recommendations for All Patients</h2>
<dl>
<dt>•</dt>
<dd>Healthcare providers should individualize the starting dose of KAZANO based on the patient's current regimen.</dd>
<dt>•</dt>
<dd>KAZANO should be taken twice daily with food with gradual dose escalation to reduce the gastrointestinal (GI) side effects due to metformin. KAZANO tablets must not be split before swallowing.</dd>
<dt>•</dt>
<dd>Dosing may be adjusted based on effectiveness and tolerability while not exceeding the maximum recommended daily dose of 25 mg alogliptin and 2000 mg metformin HCl.</dd>
<dt>•</dt>
<dd>The following doses are available:</dd>
<dt> </dt>
<dd>12.5 mg alogliptin and 500 mg metformin HCl</dd>
<dt> </dt>
<dd>12.5 mg alogliptin and 1000 mg metformin HCl</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3	DOSAGE FORMS AND STRENGTHS</h1>
<dl>
<dt>•</dt>
<dd>12.5 mg/500 mg tablets are <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, oblong, film-coated tablets with "12.5/500" debossed on one side and "322M" debossed on the other side</dd>
<dt>•</dt>
<dd>12.5 mg/1000 mg tablets are <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, oblong, film-coated tablets with "12.5/1000" debossed on one side and "322M" debossed on the other side</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4	CONTRAINDICATIONS</h1>
<p class="First">KAZANO is contraindicated in patients with:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> (e.g., serum creatinine levels ≥1.5 mg/dL for men, ≥1.4 mg/dL for women or abnormal creatinine clearance), which may also result from conditions such as <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span> (<span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>), <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span> <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.5)</a>].</span>
</dd>
<dt>•</dt>
<dd>Acute or chronic <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, including <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>. <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">Diabetic ketoacidosis</span> should be treated with insulin.</dd>
<dt>•</dt>
<dd>History of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to alogliptin or metformin, components of KAZANO, such as <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> or severe cutaneous adverse reactions.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5	WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	<span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> is a rare but serious metabolic complication that can occur due to metformin accumulation during treatment with KAZANO and is fatal in approximately 50% of cases. <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> may also occur in association with a number of pathophysiologic conditions, including <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, and whenever there is significant tissue <span class="product-label-link" type="condition" conceptid="4131044" conceptname="Hypoperfusion">hypoperfusion</span> and <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span>. <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> is characterized by elevated blood lactate levels (more than 5 mmol/L), decreased blood pH, <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span> with an increased <span class="product-label-link" type="condition" conceptid="4009397" conceptname="Anion gap">anion gap</span>, and an increased lactate/<span class="product-label-link" type="condition" conceptid="4029769" conceptname="Pyruvic acid">pyruvate</span> ratio. When metformin is implicated as the cause of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, metformin plasma levels of more than 5 mcg/mL are generally found.</p>
<p>The reported incidence of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> in patients receiving metformin HCl is very low (approximately 0.03 cases per 1000 patient-years, with approximately 0.015 fatal cases per 1000 patient-years). In more than 20,000 patient-years’ exposure to metformin in clinical trials, there were no reports of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>. Reported cases have occurred primarily in diabetic patients with significant <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, including both intrinsic <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> and renal <span class="product-label-link" type="condition" conceptid="4131044" conceptname="Hypoperfusion">hypoperfusion</span>, often in the setting of multiple concomitant medical/surgical problems and multiple concomitant medications. Patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> requiring pharmacologic management, particularly when accompanied by <span class="product-label-link" type="condition" conceptid="4131044" conceptname="Hypoperfusion">hypoperfusion</span> and <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span> due to unstable or acute failure, are at increased risk of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>. The risk of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> increases with the degree of renal dysfunction and the patient's age. The risk of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> may, therefore, be significantly decreased by regular monitoring of renal function in patients taking metformin. In particular, treatment of the elderly should be accompanied by careful monitoring of renal function. Metformin treatment should not be initiated in any patients unless measurement of creatinine clearance demonstrates that renal function is not reduced, as these patients are more susceptible to developing <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>. In addition, metformin should be promptly withheld in the presence of any condition associated with <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> or <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>. Because impaired hepatic function may significantly limit the ability to clear lactate, metformin should generally be avoided in patients with clinical or laboratory evidence of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Patients should be cautioned against excessive alcohol intake when taking metformin, because alcohol potentiates the effects of metformin on lactate metabolism. In addition, metformin should be temporarily discontinued prior to any intravascular radiocontrast study and for any surgical procedure necessitating restricted intake of food or fluids. Use of topiramate, a carbonic anhydrase inhibitor, in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> and <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> prophylaxis may frequently cause dose-dependent <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> (in controlled trials, 32% and 67% for adjunctive treatment in adult and pediatric patients, respectively, and 15% to 25% for monotherapy of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, with decrease in serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> to less than 20 mEq/L; 3% and 11% for adjunctive treatment in adult and pediatric patients, respectively, and 1% to 7% for monotherapy of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, with decrease in serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> to less than 17 mEq/L) and may exacerbate the risk of metformin-induced <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> <span class="Italics">[see<a href="#S7.1"> Drug Interactions (7.1) </a>and<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>The onset of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> often is subtle and accompanied only by nonspecific symptoms such as <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, increasing <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and nonspecific <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal distress</span>. There may be associated <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and resistant <span class="product-label-link" type="condition" conceptid="4228448" conceptname="Bradyarrhythmia">bradyarrhythmias</span> with more marked <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>.</p>
<p>Patients should be educated to promptly report these symptoms should they occur. If present, KAZANO should be withdrawn until <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> is ruled out. Serum electrolytes, <span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">ketones</span>, blood glucose, blood pH, lactate levels and blood metformin levels may be useful. Once a patient is stabilized on any dose level of metformin, GI symptoms, which are common during initiation of therapy, are unlikely to recur. Later occurrence of GI symptoms could be due to <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or other serious disease.</p>
<p>Levels of fasting venous plasma lactate above the upper limit of normal but less than 5 mmol/L in patients taking metformin do not necessarily indicate impending <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> and may be explainable by other mechanisms such as poorly controlled <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, vigorous physical activity or technical problems in sample handling<span class="Italics">.</span></p>
<p><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> should be suspected in any diabetic patient with <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> lacking evidence of <span class="product-label-link" type="condition" conceptid="4209145" conceptname="Ketoacidosis">ketoacidosis</span> (<span class="product-label-link" type="condition" conceptid="4171926" conceptname="Ketonuria">ketonuria</span> and <span class="product-label-link" type="condition" conceptid="4060404" conceptname="Acetonemia">ketonemia</span>).</p>
<p><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> is a medical emergency that must be treated in a hospital setting. In a patient with <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> who is taking metformin, the drug should be discontinued immediately and general supportive measures promptly instituted. Because metformin is dialyzable (with a clearance of up to 170 mL/min under good hemodynamic conditions), prompt hemodialysis is recommended to correct the <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> and remove the accumulated metformin. Such management often results in prompt reversal of symptoms and recovery <span class="Italics">[see<a href="#S4"> Contraindications (4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0135a0a5-9eff-4ab4-875c-0261656cbd9d"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></h2>
<p class="First">There have been postmarketing reports of <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span> in patients taking alogliptin. After initiation of KAZANO, patients should be observed carefully for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. If <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> is suspected, alogliptin should promptly be discontinued and appropriate management should be initiated. It is unknown whether patients with a history of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> are at increased risk for the development of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> while using KAZANO.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8da8d384-567b-4837-abe1-da6393cabc7d"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">There have been postmarketing reports of serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> in patients treated with alogliptin. These reactions include <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and severe cutaneous adverse reactions, including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>. If a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> is suspected, discontinue KAZANO, assess for other potential causes for the event and institute alternative treatment for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> <span class="Italics">[see <a href="#ID_75d75de1-07cc-4e8c-b8d8-151ac871419e">Adverse Reactions (6.3)</a>]</span>. Use caution in patients with a history of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> to another DPP-4 inhibitor because it is unknown whether such patients will be predisposed to <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> with KAZANO.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8eeca7bc-a1cf-47cc-ac53-198328eb8b21"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Hepatic Effects</h2>
<p class="First">There have been postmarketing reports of fatal and nonfatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> in patients taking alogliptin, although the reports contain insufficient information necessary to establish the probable cause<span class="Italics"> [see <a href="#ID_75d75de1-07cc-4e8c-b8d8-151ac871419e">Adverse Reactions (6.3)</a>]</span>. In randomized controlled studies, serum <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (ALT) elevations greater than three times the upper limit of normal (ULN) were observed: 1.3% in alogliptin-treated patients and 1.5% in all comparator-treated patients.</p>
<p>Patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> may have <span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">fatty liver</span> disease, which may cause liver test abnormalities, and they may also have other forms of liver disease, many of which can be treated or managed. Therefore, obtaining a liver test panel and assessing the patient before initiating KAZANO therapy is recommended. Because impaired hepatic function has been associated with some cases of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> with use of metformin, KAZANO should generally be avoided in patients with clinical or laboratory evidence of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>. </p>
<p>Measure liver tests promptly in patients who report symptoms that may indicate <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, including <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, right <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">upper abdominal discomfort</span>, dark urine or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>. In this clinical context, if the patient is found to have clinically significant liver enzyme elevations and if abnormal liver tests persist or worsen, KAZANO should be interrupted and investigation done to establish the probable cause. KAZANO should not be restarted in these patients without another explanation for the liver test abnormalities.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Monitoring of Renal Function</h2>
<p class="First">Metformin is substantially excreted by the kidney, and the risk of metformin accumulation and <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> increases with the degree of impairment. Therefore, KAZANO is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span><span class="Italics">.</span></p>
<p>Before initiation of KAZANO therapy and at least annually thereafter, renal function should be assessed and verified as normal. In patients in whom development of renal dysfunction is anticipated, renal function should be assessed more frequently and KAZANO discontinued if evidence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is present. Metformin treatment should not be initiated in patients ≥80 years of age unless measurement of creatinine clearance demonstrates that renal function is not reduced, as these patients are more susceptible to developing <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ac2f24a5-1659-4f67-b43b-6bc0c9b87209"></a><a name="section-5.5.1"></a><p></p>
<p class="First"><span class="Bold">Use of Concomitant Medications that May Affect Renal Function or Metformin Disposition</span></p>
<p>Concomitant medication(s) that may affect renal function or result in significant hemodynamic change or may interfere with the disposition of metformin, such as cationic drugs that are eliminated by renal tubular secretion <span class="Italics">[see<a href="#S7.2"> Drug Interactions (7.2)</a>]</span>, should be used with caution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3b2b4d50-c76a-44f9-9b79-a5399022538c"></a><a name="section-5.5.2"></a><p></p>
<p class="First"><span class="Bold">Radiological Studies and Surgical Procedures</span></p>
<p>Radiological studies involving the use of intravascular iodinated contrast materials (for example, intravenous urogram, intravenous cholangiography, angiography and computed tomography) can lead to acute alteration of renal function and have been associated with <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> in patients receiving metformin. Therefore, in patients in whom any such study is planned, KAZANO should be temporarily discontinued at the time of or prior to the procedure and withheld for 48 hours subsequent to the procedure and reinstituted only after renal function has been re-evaluated and found to be normal.</p>
<p>KAZANO therapy should be temporarily suspended for any surgical procedure (except minor procedures not associated with restricted intake of food and fluids) and should not be restarted until the patient's oral intake has resumed and renal function has been evaluated as normal.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">Hypoxic</span> States</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">Cardiovascular collapse</span> (<span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>) from whatever cause, acute <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> and other conditions characterized by <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span> have been associated with <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> and may also cause prerenal <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>. When such events occur in patients on KAZANO therapy, the drug should be promptly discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Alcohol Intake</h2>
<p class="First">Alcohol is known to potentiate the effect of metformin on lactate metabolism. Patients, therefore, should be warned against excessive alcohol intake while receiving KAZANO.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Vitamin B12 Levels</h2>
<p class="First">In controlled, 29-week clinical trials of immediate-release metformin, a decrease to subnormal levels of previously normal serum vitamin B<span class="Sub">12</span> levels, without clinical manifestations, was observed in approximately 7% of patients. Such decrease, possibly due to interference with B<span class="Sub">12</span> absorption from the B<span class="Sub">12</span>-intrinsic factor complex is, however, very rarely associated with <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and appears to be rapidly reversible with discontinuation of metformin or vitamin B<span class="Sub">12</span> supplementation. Measurement of hematologic parameters on an annual basis is advised in patients on KAZANO, and any apparent abnormalities should be appropriately investigated and managed. Certain individuals (those with inadequate vitamin B<span class="Sub">12</span> or calcium intake or absorption) appear to be predisposed to developing subnormal vitamin B<span class="Sub">12</span> levels. In these patients, routine serum vitamin B<span class="Sub">12</span> measurements at two- to three-year intervals may be useful.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.9"></a><p></p>
<h2>5.9	Use with Medications Known to Cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_138ba8e3-79e6-48c3-a423-1a68bf8066a8"></a><a name="section-5.9.1"></a><p></p>
<p class="First"><span class="Bold">Alogliptin</span></p>
<p>Insulin and insulin secretagogues, such as sulfonylureas, are known to cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Therefore, a lower dose of insulin or insulin secretagogue may be required to reduce the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> when used in combination with KAZANO.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_32d30e59-6481-46ce-b77b-ae7380df5abd"></a><a name="section-5.9.2"></a><p></p>
<p class="First"><span class="Bold">Metformin Hydrochloride</span></p>
<p><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> does not occur in patients receiving metformin alone under usual circumstances of use but could occur when caloric intake is deficient, when strenuous exercise is not compensated by caloric supplementation or during concomitant use with other glucose-lowering agents (such as sulfonylureas and insulin) or ethanol. Elderly, debilitated or malnourished patients and those with adrenal or <span class="product-label-link" type="condition" conceptid="4254542" conceptname="Hypopituitarism">pituitary insufficiency</span> or alcohol <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> are particularly susceptible to hypoglycemic effects. <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> may be difficult to recognize in the elderly and in people who are taking β-adrenergic blocking drugs.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_af7abe64-3252-4f5c-87bb-1ab5210cee41"></a><a name="section-5.10"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">5.10 Severe and Disabling <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">There have been postmarketing reports of severe and disabling <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> in patients taking DPP-4 inhibitors. The time to onset of symptoms following initiation of drug therapy varied from one day to years. Patients experienced a relief of symptoms upon discontinuation of the medication. A subset of patients experienced a recurrence of symptoms when restarting the same drug or a different DPP-4 inhibitor. Consider DPP-4 inhibitors as a possible cause for severe <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span> and discontinue drug if appropriate. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Macrovascular Outcomes</h2>
<p class="First">There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with KAZANO or any other antidiabetic drug.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6	ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9353c049-ca75-4369-8496-675e8f44efea"></a><a name="section-6.1.1"></a><p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_64ae2de2-470b-49da-b40a-aa2d814859b9"></a><a name="section-6.1.1.1"></a><p></p>
<p class="First"><span class="Bold">Alogliptin and Metformin Hydrochloride</span></p>
<p>Over 2700 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> have received alogliptin coadministered with metformin in four large, randomized, double-blind controlled clinical trials. The mean exposure to KAZANO was 58 weeks, with more than 1400 subjects treated for more than one year. These included two 26-week placebo-controlled studies, one 52-week active control study and an interim analysis of a 104-week active-controlled study. In the KAZANO arm, the mean duration of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> was approximately six years, the mean body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index (BMI) was 31 kg/m<span class="Sup">2</span> (56% of patients had a BMI ≥30 kg/m<span class="Sup">2</span>) and the mean age was 55 years (18% of patients ≥65 years of age). </p>
<p>In a pooled analysis of these four controlled clinical studies, the overall incidence of adverse reactions was 74% in patients treated with KAZANO compared to 75% treated with placebo. Overall discontinuation of therapy due to adverse events was 6.2% with KAZANO compared to 1.9% in placebo, 6.4% in metformin and 5.0% in alogliptin.</p>
<p>Adverse reactions reported in ≥4% of patients treated with KAZANO and more frequently than in patients who received alogliptin, metformin or placebo are summarized in Table 1.</p>
<table width="100%">
<col width="35%">
<col width="16%">
<col width="16%">
<col width="16%">
<col width="16%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>KAZANO − includes data pooled for patients receiving alogliptin 25 and 12.5 mg combined with various dose of metformin</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Alogliptin − includes data pooled for patients receiving alogliptin 25 and 12.5 mg</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>Metformin − includes data pooled for patients receiving various doses of metformin</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="5" valign="top"><p class="First"><span class="Bold">Table 1. Adverse Reactions Reported in ≥4% of Patients Treated with KAZANO and More Frequently than in Patients Receiving Either Alogliptin, Metformin or Placebo</span></p></td></tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="5" valign="middle"><p class="First"><span class="Bold">Number of Patients (%)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">KAZANO</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Alogliptin</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Metformin</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Placebo</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=2794</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=222</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=1592</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=106</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">224 (8.0)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">6 (2.7)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">105 (6.6)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">3 (2.8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">191 (6.8)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">7 (3.2)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">93 (5.8)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">2 (1.9)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">155 (5.5)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">4 (1.8)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">105 (6.6)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">3 (2.8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">154 (5.5)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">5 (2.3)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">96 (6.0)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">6 (5.7)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">149 (5.3)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">11 (5.0)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">74 (4.6)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">3 (2.8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">119 (4.3)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1 (0.5)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">72 (4.5)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1 (0.9)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">116 (4.2)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">4 (1.8)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">59 (3.7)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">2 (1.9)</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></span></p>
<p>In a 26-week, double-blind, placebo-controlled study of alogliptin in combination with metformin, the number of patients reporting <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was 1.9% in the alogliptin 12.5 mg with metformin HCl 500 mg, 5.3% in the alogliptin 12.5 mg with metformin HCl 1000 mg, 1.8% in the metformin HCl 500 mg and 6.3% in the metformin HCl 1000 mg treatment groups.</p>
<p>In a 26-week placebo-controlled study of alogliptin 25 mg administered once daily as add-on to metformin regimen, the number of patients reporting hypoglycemic events was 0% in the alogliptin with metformin and 2.9% in the placebo treatment groups.</p>
<p>In a 52-week, active-controlled, double-blind study of alogliptin once daily as add-on therapy to the combination of pioglitazone 30 mg and metformin compared to the titration of pioglitazone 30 mg to 45 mg and metformin, the number of patients reporting <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was 4.5% in the alogliptin 25 mg with pioglitazone 30 mg and metformin group versus 1.5% in the pioglitazone 45 mg with metformin group.</p>
<p>In an interim analysis conducted in a 104-week, double-blind, active-controlled study of alogliptin 25 mg in combination with metformin, the number of patients reporting <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was 1.4% in the alogliptin 25 mg with metformin group versus 23.8% in the glipizide with metformin group.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1653080d-1d13-4d76-a098-77230901478e"></a><a name="section-6.1.1.2"></a><p></p>
<p class="First"><span class="Bold">Alogliptin</span></p>
<p>Approximately 8500 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> have been treated with alogliptin in 14 randomized, double-blind, controlled clinical trials with approximately 2900 subjects randomized to placebo and approximately 2200 to an active comparator. The mean exposure to alogliptin was 40 weeks, with more than 2400 subjects treated for more than one year. Among these patients, 63% had a history of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, 51% had a history of <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>, 25% had a history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, 8% had a history of <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> and 7% had a history of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. The mean duration of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> was seven years, the mean BMI was 31 kg/m<span class="Sup">2</span> (51% of patients had a BMI ≥30 kg/m<span class="Sup">2</span>) and the mean age was 57 years (24% of patients ≥65 years of age).</p>
<p>Two placebo-controlled monotherapy trials of 12 and 26 weeks of duration were conducted in patients treated with alogliptin 12.5 mg daily, alogliptin 25 mg daily and placebo. Four placebo-controlled add-on combination therapy trials of 26 weeks’ duration were also conducted: with metformin, with a sulfonylurea, with a thiazolidinedione and with insulin.</p>
<p>Four placebo-controlled and one active-controlled trials of 16 weeks up through two years in duration were conducted in combination with metformin, in combination with pioglitazone and with pioglitazone added to a background of metformin therapy.</p>
<p>Three active-controlled trials of 52 weeks in duration were conducted in patients treated with pioglitazone and metformin, in combination with metformin and as monotherapy compared to glipizide.</p>
<p>In a pooled analysis of these 14 controlled clinical trials, the overall incidence of adverse events was 66% in patients treated with alogliptin 25 mg compared to 62% with placebo and 70% with active comparator. Overall discontinuation of therapy due to adverse events was 4.7% with alogliptin 25 mg compared to 4.5% with placebo or 6.2% with active comparator.</p>
<p>Adverse reactions reported in ≥4% of patients treated with alogliptin 25 mg and more frequently than in patients who received placebo are summarized in Table 2.</p>
<table width="100%">
<col width="40%">
<col width="20%">
<col width="20%">
<col width="20%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="4" valign="top"><p class="First"><span class="Bold">Table 2. Adverse Reactions Reported in ≥4% Patients Treated with Alogliptin 25 mg and More Frequently than in Patients Given Placebo in Pooled Studies</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="3" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" colspan="3" valign="middle"><p class="First"><span class="Bold">Number of Patients (%)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First"><span class="Bold">Alogliptin </span></p>
<p><span class="Bold">25 mg</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Placebo</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Active <br>Comparator</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=5902</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=2926</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=2257</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">257 (4.4)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">89 (3.0)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">113 (5.0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">247 (4.2)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">72 (2.5)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">121 (5.4)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">247 (4.2)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">61 (2.1)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">113 (5.0)</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></span></p>
<p>In the clinical trial program, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> was reported in 11 of 5902 (0.2%) patients receiving alogliptin 25 mg daily compared to five of 5183 (˂0.1%) patients receiving all comparators.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span></p>
<p>In a pooled analysis, the overall incidence of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> was 0.6% with alogliptin 25 mg compared to 0.8% with all comparators. A single event of <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span> was reported in a patient treated with alogliptin 25 mg.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></span></p>
<p>Hypoglycemic events were documented based upon a blood glucose value and/or clinical signs and symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
<p>In the monotherapy study, the incidence of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was 1.5% in patients treated with alogliptin compared to 1.6% with placebo. The use of alogliptin as add-on therapy to glyburide or insulin did not increase the incidence of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> compared to placebo. In a monotherapy study comparing alogliptin to a sulfonylurea in elderly patients, the incidence of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was 5.4% with alogliptin compared to 26% with glipizide.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7c6f0d35-91d1-48f1-aeaf-54579e3172ec"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Bold">Metformin Hydrochloride</span></p>
<table width="100%">
<col width="32%">
<col width="34%">
<col width="34%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Reactions that were more common in metformin than placebo-treated patients</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="3" valign="top"><p class="First"><span class="Bold">Table 3. Most Common Adverse Reactions (≥5%) in a Placebo-Controlled Clinical Study of Metformin Monotherapy</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Adverse Reaction </span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First"><span class="Bold">Metformin </span></p>
<p><span class="Bold">Monotherapy</span><br><span class="Bold">(n=141)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Placebo</span><br><span class="Bold">(n=145)</span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First"><span class="Bold">% of Patients</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">53.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">11.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">25.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">12.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">5.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">9.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">5.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Indigestion</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">7.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">4.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal discomfort</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">6.4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">4.8</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">5.7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">4.8</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Laboratory Abnormalities</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4b2b2fc0-01cb-4527-889e-c55660ca46e6"></a><a name="section-6.2.1"></a><p></p>
<p class="First"><span class="Bold">Alogliptin and Metformin Hydrochloride</span></p>
<p>No clinically meaningful differences were observed among treatment groups regarding hematology, serum chemistry or urinalysis results.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d035410d-4a0e-46c9-bda6-3126cbff5f08"></a><a name="section-6.2.2"></a><p></p>
<p class="First"><span class="Bold">Alogliptin</span></p>
<p>No clinically meaningful changes in hematology, serum chemistry or urinalysis were observed in patients treated with alogliptin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5448d324-84b4-4205-87c8-93d1b3d90406"></a><a name="section-6.2.3"></a><p></p>
<p class="First"><span class="Bold">Metformin Hydrochloride</span></p>
<p>Metformin may lower serum vitamin B12 concentrations. Measurement of hematologic parameters on an annual basis is advised in patients on KAZANO, and any apparent abnormalities should be appropriately investigated and managed <span class="Italics">[see<a href="#S5.6"> Warnings and Precautions (5.8)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_75d75de1-07cc-4e8c-b8d8-151ac871419e"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Postmarketing Experience</h2>
<p class="First"><span class="Bold">Alogliptin</span></p>
<p>The following adverse reactions have been identified during the postmarketing use of alogliptin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> include <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and severe cutaneous adverse reactions, including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, hepatic enzyme elevations, <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">fulminant hepatic failure</span>, severe and disabling <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> and <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span> <span class="Italics">[see Warnings and Precautions (<a href="#ID_0135a0a5-9eff-4ab4-875c-0261656cbd9d">5.2</a>, <a href="#ID_8da8d384-567b-4837-abe1-da6393cabc7d">5.3</a>, <a href="#ID_8eeca7bc-a1cf-47cc-ac53-198328eb8b21">5.4</a>, <a href="#ID_af7abe64-3252-4f5c-87bb-1ab5210cee41">5.10</a>)</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7	DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5494ec6d-c442-4090-a3aa-6c16b12f6a7c"></a><a name="section-7.1"></a><p></p>
<p class="First"><span class="Bold">Alogliptin</span></p>
<p>Alogliptin is primarily renally excreted and CYP-related metabolism is negligible. No drug-drug interactions were observed with the CYP-substrates or inhibitors tested or with renally excreted drugs<span class="Italics"> [see<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>.</p>
<p><span class="Bold">Metformin Hydrochloride</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.2"></a><p></p>
<h2>7.1	Carbonic Anhydrase Inhibitors </h2>
<p class="First">Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) frequently decrease serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> and induce nonanion gap, hyperchloremic <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>. Concomitant use of these drugs may induce <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>. Use these drugs with caution in patients treated with metformin, as the risk of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> may increase.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.3"></a><p></p>
<h2>7.2	Cationic Drugs</h2>
<p class="First">Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. Although such interactions remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of KAZANO and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.4"></a><p></p>
<h2>7.3	The Use of Metformin with Other Drugs</h2>
<p class="First">Certain drugs tend to produce <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and may lead to loss of glycemic control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs and isoniazid. When such drugs are administered to a patient receiving KAZANO, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving KAZANO, the patient should be observed closely for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8	USE IN SPECIFIC POPULATIONS </h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1	Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="ID_a2a3a26f-8c98-4098-9834-49af4cd12f7d"></a><a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Category B</span></p>
<p><span class="Bold">Alogliptin and Metformin Hydrochloride</span></p>
<p>There are no adequate and well-controlled studies in pregnant women with KAZANO or its individual components. Based on animal data, KAZANO is not predicted to increase the risk of developmental abnormalities. Because animal reproduction studies are not always predictive of human risk and exposure, KAZANO, like other antidiabetic medications, should be used during pregnancy only if clearly needed.</p>
<p>No treatment-related fetal abnormalities occurred following concomitant administration of 100 mg/kg alogliptin with 150 mg/kg metformin to pregnant rats, or approximately 28 and two times the clinical dose of alogliptin (25 mg) and metformin (2000 mg), respectively (based on AUC).</p>
<p><span class="Bold">Alogliptin</span></p>
<p>Alogliptin administered to pregnant rabbits and rats during the period of organogenesis was not teratogenic at doses of up to 200 and 500 mg/kg, or 149 times and 180 times, respectively, the clinical dose based on plasma drug exposure (AUC). </p>
<p>Doses of alogliptin up to 250 mg/kg (approximately 95 times clinical exposure based on AUC) given to pregnant rats from gestation Day 6 to lactation Day 20 did not harm the developing embryo or adversely affect growth and development of offspring. </p>
<p>Placental transfer of alogliptin into the fetus was observed following oral dosing to pregnant rats.</p>
<p><span class="Bold">Metformin Hydrochloride</span></p>
<p>Metformin was not teratogenic in rats and rabbits at doses up to 600 mg/kg, which represents an exposure of about two and six times the MRHD dose of 2000 mg based on body surface area comparisons for rats and rabbits, respectively. Metformin HCl should not be used during pregnancy unless clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3	Nursing Mothers</h2>
<p class="First">No studies have been conducted with the combined components of KAZANO. In studies performed with the individual components, both alogliptin and metformin are secreted in the milk of lactating rats. It is not known whether alogliptin and/or metformin are secreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when KAZANO is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4	Pediatric Use</h2>
<p class="First">Safety and effectiveness of KAZANO in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5	Geriatric Use</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3a11aa46-6b09-4815-baa2-8b105708e7f7"></a><a name="section-8.4.1"></a><p></p>
<p class="First"><span class="Bold">Alogliptin and Metformin Hydrochloride</span></p>
<p>Elderly patients are more likely to have decreased renal function. Because metformin is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, carefully monitor renal function in the elderly and use KAZANO with caution as age increases <span class="Italics">[see<a href="#S5.2"> Warnings and Precautions (5.5) </a>and<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>Of the total number of patients (N = 2095) in clinical safety and efficacy studies, 343 (16.4%) patients were 65 years and older and 37 (1.8%) patients were 75 years and older. No overall differences in safety or effectiveness were observed between these patients and younger patients. While this and other reported clinical experiences have not identified differences in responses between the elderly and younger patients, greater sensitivity of some older individuals cannot be excluded.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_75c16bf6-38f5-41b6-8c1a-435004dcc085"></a><a name="section-8.4.2"></a><p></p>
<p class="First"><span class="Bold">Alogliptin</span></p>
<p>Of the total number of patients (N=8507) in clinical safety and efficacy studies treated with alogliptin, 2064 (24.3%) patients were 65 years and older and 341 (4%) patients were 75 years and older. No overall differences in safety or effectiveness were observed between patients 65 years and over and younger patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_cf2bba2a-c4d1-4ff5-8ae7-84d73f4c6edb"></a><a name="section-8.4.3"></a><p></p>
<p class="First"><span class="Bold">Metformin Hydrochloride</span></p>
<p>Controlled studies of metformin did not include sufficient numbers of subjects age 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.</p>
<p>Metformin should only be used in patients with normal renal function. The initial and maintenance dosing of metformin should be conservative in patients with advanced age due to the potential for decreased renal function in this population <span class="Italics">[see<a href="#S4"> Contraindications (4)</a>,<a href="#S5.2"> Warnings and Precautions (5.5)</a> and<a href="#S12.3"> Clinical Pharmacology (12.3)</a>].</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10	OVERDOSAGE </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d6c38c21-a970-4b61-b479-ca8f6cccd95d"></a><a name="section-9.1"></a><p></p>
<p class="First"><span class="Bold">Alogliptin</span></p>
<p>The highest doses of alogliptin administered in clinical trials were single doses of 800 mg to healthy subjects and doses of 400 mg once daily for 14 days to patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (equivalent to 32 times and 16 times the recommended clinical dose, respectively). No dose-limiting adverse events were observed at these doses.</p>
<p>In the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, it is reasonable to institute the necessary clinical monitoring and supportive therapy as dictated by the patient's clinical status. Per clinical judgment, it may be reasonable to initiate removal of unabsorbed material from the gastrointestinal tract.</p>
<p>Alogliptin is minimally dialyzable; over a three-hour hemodialysis session, approximately 7% of the drug was removed. Therefore, hemodialysis is unlikely to be beneficial in an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> situation. It is not known if alogliptin is dialyzable by peritoneal dialysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_af5c091c-c167-4920-8433-750a6daea1dc"></a><a name="section-9.2"></a><p></p>
<p class="First"><span class="Bold">Metformin Hydrochloride</span></p>
<p><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> of metformin has occurred, including ingestion of amounts greater than 50 grams. <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> was reported in approximately 10% of cases, but no causal association with metformin has been established. <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> has been reported in approximately 32% of metformin <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> cases <span class="Italics">[see<a href="#S5.1"> Warnings and Precautions (5.1)</a>]</span>. Metformin is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions. Therefore, hemodialysis may be useful for removal of accumulated drug from patients in whom metformin overdosage is suspected.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 	DESCRIPTION</h1>
<p class="First">KAZANO tablets contain two oral antihyperglycemic drugs used in the management of type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>: alogliptin and metformin hydrochloride.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_96029719-753d-4dcd-a597-14d82c0adcc8"></a><a name="section-10.1"></a><p></p>
<p class="First"><span class="Bold">Alogliptin</span></p>
<p>Alogliptin is a selective, orally bioavailable inhibitor of the enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt, which is identified as 2-({6-[(3<span class="Italics">R</span>)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2<span class="Italics">H</span>)-yl}methyl)benzonitrile monobenzoate. It has a molecular formula of C<span class="Sub">18</span>H<span class="Sub">21</span>N<span class="Sub">5</span>O<span class="Sub">2</span>•C<span class="Sub">7</span>H<span class="Sub">6</span>O<span class="Sub">2</span> and a molecular weight of 461.51 daltons; the structural formula is:</p>
<div class="Figure">
<a name="id1174"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83cb7914-a683-47bb-a713-f2bc6a596bd2&amp;name=c953d30e-0172-491a-b227-36b1636b6ad2-01.jpg">
</div>
<p>Alogliptin benzoate is a white to off-white crystalline powder, containing one asymmetric carbon in the aminopiperidine moiety. It is soluble in dimethylsulfoxide, sparingly soluble in water and methanol, slightly soluble in ethanol and very slightly soluble in octanol and isopropyl acetate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a1d071ed-a042-4c5e-bff9-1dcc76cd8564"></a><a name="section-10.2"></a><p></p>
<p class="First"><span class="Bold">Metformin Hydrochloride</span></p>
<p>Metformin hydrochloride (<span class="Italics">N,N</span>-dimethylimidodicarbonimidic diamide hydrochloride) is not chemically or pharmacologically related to any other classes of oral antihyperglycemic agents. Metformin hydrochloride is a white to off-white crystalline compound with a molecular formula of C<span class="Sub">4</span>H<span class="Sub">11</span>N<span class="Sub">5</span>•HCl and a molecular weight of 165.63. Metformin hydrochloride is freely soluble in water and is practically insoluble in acetone, ether and chloroform. The pKa of metformin is 12.4. The pH of a 1% aqueous solution of metformin hydrochloride is 6.68. The structural formula is as shown:</p>
<div class="Figure">
<a name="id1195"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83cb7914-a683-47bb-a713-f2bc6a596bd2&amp;name=c953d30e-0172-491a-b227-36b1636b6ad2-02.jpg">
</div>
<p>KAZANO is available as a tablet for oral administration containing 17 mg alogliptin benzoate equivalent to 12.5 mg alogliptin and:</p>
<dl>
<dt>•</dt>
<dd>500 mg metformin hydrochloride (12.5 mg/500 mg) or</dd>
<dt>•</dt>
<dd>1000 mg metformin hydrochloride (12.5 mg/1000 mg).</dd>
</dl>
<p>KAZANO tablets contain the following inactive ingredients: mannitol, microcrystalline cellulose, povidone, crospovidone, and magnesium stearate; the tablets are film-coated with hypromellose 2910, talc, titanium dioxide and ferric oxide yellow.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12	CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1	Mechanism of Action</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e2a8666e-1b5c-4354-ae3c-2dcf766928df"></a><a name="section-11.1.1"></a><p></p>
<p class="First"><span class="Bold">Alogliptin and Metformin Hydrochloride</span></p>
<p>KAZANO combines two antihyperglycemic agents with complementary and distinct mechanisms of action to improve glycemic control in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>: alogliptin, a selective inhibitor of DPP-4, and metformin HCl, a member of the biguanide class.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_908f188f-ec90-48ff-9334-e3cf88aa76ff"></a><a name="section-11.1.2"></a><p></p>
<p class="First"><span class="Bold">Alogliptin</span></p>
<p>Increased concentrations of the incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released into the bloodstream from the small intestine in response to meals. These hormones cause insulin release from the pancreatic beta cells in a glucose-dependent manner but are inactivated by the DPP-4 enzyme within minutes. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, reducing hepatic glucose production. In patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, concentrations of GLP-1 are reduced but the insulin response to GLP-1 is preserved. Alogliptin is a DPP-4 inhibitor that slows the inactivation of the incretin hormones, thereby increasing their bloodstream concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. Alogliptin selectively binds to and inhibits DPP-4 but not DPP-8 or DPP-9 activity <span class="Italics">in vitro</span> at concentrations approximating therapeutic exposures.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7c5749af-7d7f-43e7-96b7-2b644eddc318"></a><a name="section-11.1.3"></a><p></p>
<p class="First"><span class="Bold">Metformin Hydrochloride</span></p>
<p>Metformin is a biguanide that improves glucose tolerance in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Metformin does not produce <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or in healthy subjects except in special circumstances <span class="Italics">[see<a href="#S5.7"> Warnings and Precautions (5.9)</a>]</span> and does not cause <span class="product-label-link" type="condition" conceptid="4307509" conceptname="Hyperinsulinism">hyperinsulinemia</span>. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and daylong plasma insulin response may actually decrease.</p>
</div>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2	Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_24986b7c-7389-483c-a5a7-6ca630bca8f6"></a><a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Bold">Alogliptin</span></p>
<p>Single-dose administration of alogliptin to healthy subjects resulted in a peak inhibition of DPP-4 within two to three hours after dosing. The peak inhibition of DPP-4 exceeded 93% across doses of 12.5 mg to 800 mg. Inhibition of DPP-4 remained above 80% at 24 hours for doses greater than or equal to 25 mg. Peak and total exposure over 24 hours to active GLP-1 were three- to four-fold greater with alogliptin (at doses of 25 to 200 mg) than placebo. In a 16-week, double-blind, placebo-controlled study, alogliptin 25 mg demonstrated decreases in postprandial glucagon while increasing postprandial active GLP-1 levels compared to placebo over an eight-hour period following a standardized meal. It is unclear how these findings relate to changes in overall glycemic control in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. In this study, alogliptin 25 mg demonstrated decreases in two-hour postprandial glucose compared to placebo (-30 mg/dL versus 17 mg/dL, respectively).</p>
<p>Multiple-dose administration of alogliptin to patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> also resulted in a peak inhibition of DPP-4 within one to two hours and exceeded 93% across all doses (25 mg, 100 mg and 400 mg) after a single dose and after 14 days of once-daily dosing. At these doses of alogliptin, inhibition of DPP-4 remained above 81% at 24 hours after 14 days of dosing.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3	Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2e0e279a-d108-42bc-ad9b-654155e5cc6a"></a><a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Bold">Absorption and Bioavailability</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_84170ed2-09f3-4f0c-8c72-69eda6d894de"></a><a name="section-11.3.1.1"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Alogliptin and Metformin Hydrochloride</span></span></p>
<p>In bioequivalence studies of KAZANO, the area under the curve (AUC) and maximum concentration (C<span class="Sub">max</span>) of both the alogliptin and the metformin component following a single dose of the combination tablet were bioequivalent to the alogliptin 12.5 mg concomitantly administered with metformin HCl 500 or 1000 mg tablets under fasted conditions in healthy subjects. Administration of KAZANO with food resulted in no change in total exposure (AUC) of alogliptin and metformin. Mean peak plasma concentrations of alogliptin and metformin were decreased by 13% and 28%, respectively, when administered with food. There was no change in time to peak plasma concentrations (T<span class="Sub">max</span>) for alogliptin under fed conditions, however, there was a delayed T<span class="Sub">max</span> for metformin of 1.5 hours. These changes are not likely to be clinically significant.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f6c2d55d-a3bd-489c-ac2d-a91aa90b8d72"></a><a name="section-11.3.1.2"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Alogliptin</span></span></p>
<p>The absolute bioavailability of alogliptin is approximately 100%. Administration of alogliptin with a high-fat meal resulted in no change in total and peak exposure to alogliptin. Alogliptin may therefore be administered with or without food.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d24010c9-2fa6-4b05-af5d-68c13a2efa6a"></a><a name="section-11.3.1.3"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Metformin Hydrochloride</span></span></p>
<p>The absolute bioavailability of metformin following administration of a 500 mg metformin HCl tablet given under fasting conditions is approximately 50% to 60%. Studies using single oral doses of metformin HCl tablets 500 mg to 1500 mg and 850 mg to 2550 mg indicate that there is a lack of dose proportionality with increasing doses, which is due to decreased absorption rather than an alteration in elimination. Food decreases the extent of and slightly delays the absorption of metformin, as shown by approximately a 40% lower mean peak plasma concentration (C<span class="Sub">max</span>), a 25% lower area under the plasma concentration versus time curve (AUC), and a 35-minute prolongation of time to peak plasma concentration (T<span class="Sub">max</span>) following administration of a single 850 mg tablet of metformin HCl with food compared to the same tablet strength administered fasting. The clinical relevance of these decreases is unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4820f7ce-dafd-4ef5-ae0b-0fe26aeb8795"></a><a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Bold">Distribution</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2172f5b7-cd8a-4bd9-b279-a29ac4a87751"></a><a name="section-11.3.2.1"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Alogliptin</span></span></p>
<p>Following a single, 12.5 mg intravenous dose of alogliptin to healthy subjects, the volume of distribution during the terminal phase was 417 L, indicating that the drug is well distributed into tissues.</p>
<p>Alogliptin is 20% bound to plasma proteins.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_987e5725-7a37-493a-93b0-92d720b04eb4"></a><a name="section-11.3.2.2"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Metformin Hydrochloride</span></span></p>
<p>The apparent volume of distribution (V/F) of metformin following single oral doses of immediate release metformin HCl tablets 850 mg averaged 654 ± 358 L. Metformin is negligibly bound to plasma proteins. Metformin partitions into erythrocytes, most likely as a function of time. At usual clinical doses and dosing schedules of metformin, steady-state plasma concentrations of metformin are reached within 24 to 48 hours and are generally less than 1 mcg/mL. During controlled clinical trials, which served as the basis for approval for metformin, maximum metformin plasma levels did not exceed 5 mcg/mL, even at maximum doses.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0b0e7bec-41cc-47b5-8b23-655d795ad237"></a><a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Bold">Metabolism</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_899b2245-7db4-4a6f-a22d-645ed2e0df7b"></a><a name="section-11.3.3.1"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Alogliptin</span></span></p>
<p>Alogliptin does not undergo extensive metabolism and 60% to 71% of the dose is excreted as unchanged drug in the urine.</p>
<p>Two minor metabolites were detected following administration of an oral dose of [<span class="Sup">14</span>C] alogliptin, <span class="Italics">N</span>-demethylated, M-I (less than 1% of the parent compound), and <span class="Italics">N</span>-acetylated alogliptin, M-II (less than 6% of the parent compound). M-I is an active metabolite and is an inhibitor of DPP-4 similar to the parent molecule; M-II does not display any inhibitory activity toward DPP-4 or other DPP-related enzymes. <span class="Italics">In vitro </span>data indicate that CYP2D6 and CYP3A4 contribute to the limited metabolism of alogliptin.</p>
<p>Alogliptin exists predominantly as the (<span class="Italics">R</span>)-enantiomer (more than 99%) and undergoes little or no chiral conversion <span class="Italics">in vivo</span> to the (<span class="Italics">S</span>)-enantiomer. The (<span class="Italics">S</span>)-enantiomer is not detectable at the 25 mg dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_77e0882c-d79f-4c76-89fe-c7f15b08050a"></a><a name="section-11.3.3.2"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Metformin Hydrochloride</span></span></p>
<p>Intravenous single-dose studies in healthy subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been identified in humans) or biliary excretion.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7598d352-dfbb-4283-8862-c8ea49c0ee47"></a><a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Bold">Excretion and Elimination</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f70116d2-d95c-43d5-aa26-19ea65de4528"></a><a name="section-11.3.4.1"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Alogliptin</span></span></p>
<p>The primary route of elimination of [<span class="Sup">14</span>C] alogliptin-derived radioactivity occurred via renal excretion (76%) with 13% recovered in the feces, achieving a total recovery of 89% of the administered radioactive dose. The renal clearance of alogliptin (9.6 L/hr) indicates some active renal tubular secretion and systemic clearance was 14.0 L/hr.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5e94bfbc-db9e-438c-8293-4225a5e68999"></a><a name="section-11.3.4.2"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Metformin Hydrochloride</span></span></p>
<p>Renal clearance is approximately 3.5 times greater than creatinine clearance, which indicates that tubular secretion is the major route of metformin elimination. Following oral administration, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours, with a plasma elimination half-life of approximately 6.2 hours. In blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> may be a compartment of distribution.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e8b6e0bc-b71c-459e-a516-59219a2c8625"></a><a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Bold">Special Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3c37567b-16d4-444a-9225-61aecf185d50"></a><a name="section-11.3.5.1"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_464aff99-2195-4563-a895-ddd4761c3699"></a><a name="section-11.3.5.1.1"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Alogliptin and Metformin Hydrochloride</span></span></p>
<p>Use of KAZANO in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> increases the risk for <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>. Because KAZANO contains metformin, KAZANO is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see<a href="#S4"> Contraindications (4) </a>and<a href="#S5.2"> Warnings and Precautions (5.5)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bc4d4119-cd5a-4bef-b19a-207cdc2967fe"></a><a name="section-11.3.5.2"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ac0c8f35-6b88-48e4-b696-8982ec9044d3"></a><a name="section-11.3.5.2.1"></a><p></p>
<p class="First">KAZANO is not recommended in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. KAZANO contains metformin and use of metformin in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> has been associated with some cases of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> <span class="Italics">[see <a href="#ID_8eeca7bc-a1cf-47cc-ac53-198328eb8b21">Warnings and Precautions (5.4)</a>].</span></p>
<p><span class="Bold"><span class="Italics">Alogliptin</span></span></p>
<p>Total exposure to alogliptin was approximately 10% lower and peak exposure was approximately 8% lower in patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Grade B) compared to healthy subjects. The magnitude of these reductions is not considered to be clinically meaningful. Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Grade C) have not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_142195f9-4461-4caf-9cfd-38abe0d5deaa"></a><a name="section-11.3.5.2.2"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Metformin Hydrochloride</span></span></p>
<p>No pharmacokinetic studies of metformin have been conducted in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d50fa84f-8135-4f5e-b8b5-a46f4a5f4eb8"></a><a name="section-11.3.5.3"></a><p></p>
<p class="First"><span class="Bold">Gender</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7d19c4a6-1bed-4c80-b421-3600cdafc358"></a><a name="section-11.3.5.3.1"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Alogliptin</span></span></p>
<p>No dose adjustment is necessary based on gender. Gender did not have any clinically meaningful effect on the pharmacokinetics of alogliptin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_330fbee7-0fa8-4344-9f64-5fb59231c178"></a><a name="section-11.3.5.3.2"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Metformin Hydrochloride</span></span></p>
<p>Metformin pharmacokinetic parameters did not differ significantly between normal subjects and patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> when analyzed according to gender. Similarly, in controlled clinical studies in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, the antihyperglycemic effect of metformin hydrochloride tablets was comparable in males and females.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3dae255f-de08-4129-807c-94313954c949"></a><a name="section-11.3.5.4"></a><p></p>
<p class="First"><span class="Bold">Geriatric</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ecf6feaf-28cf-4240-98e7-4d7f2750b616"></a><a name="section-11.3.5.4.1"></a><p></p>
<p class="First">KAZANO contains metformin, which is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.5)</a>]</span>. Due to declining renal function in the elderly, measurement of creatinine clearance should be obtained prior to initiation of therapy. Do not use KAZANO if renal function is not within normal range.</p>
<p><span class="Bold"><span class="Italics">Alogliptin</span></span></p>
<p>No dose adjustment is necessary based on age. Age did not have any clinically meaningful effect on the pharmacokinetics of alogliptin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e1cbf8f7-f19b-4715-97bd-334736e89231"></a><a name="section-11.3.5.4.2"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Metformin Hydrochloride</span></span></p>
<p>Limited data from controlled pharmacokinetic studies of metformin in healthy elderly subjects suggest that total plasma clearance of metformin is decreased, the half-life is prolonged, and C<span class="Sub">max</span> is increased, compared to healthy young subjects. From these data it appears that the change in metformin pharmacokinetics with aging is primarily accounted for by a change in renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b2b3b776-fc6d-472a-9cc2-71cb18d8ab06"></a><a name="section-11.3.5.5"></a><p></p>
<p class="First"><span class="Bold">Pediatrics</span></p>
<p>Studies characterizing the pharmacokinetics of alogliptin in pediatric patients have not been performed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_eb8a5412-501c-4c94-85ea-e3e03215f8cb"></a><a name="section-11.3.5.6"></a><p></p>
<p class="First"><span class="Bold">Race</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4dfde93d-90ce-4507-ad55-f3be2cc8d76e"></a><a name="section-11.3.5.6.1"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Alogliptin</span></span></p>
<p>No dose adjustment of alogliptin is necessary based on race. Race (white, black and Asian) did not have any clinically meaningful effect on the pharmacokinetics of alogliptin.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8624c6f0-f1b1-4374-9b12-9b040be98bfa"></a><a name="section-11.3.5.6.1.1"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Metformin Hydrochloride</span></span></p>
<p>No studies of metformin pharmacokinetic parameters according to race have been performed. In controlled clinical studies of metformin in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, the antihyperglycemic effect was comparable in whites (n=249), blacks (n=51) and Hispanics (n=24).</p>
<p><span class="Bold">Drug Interactions</span></p>
<p><span class="Bold">Alogliptin and Metformin Hydrochloride</span></p>
<p>Administration of alogliptin 100 mg once daily with metformin HCl 1000 mg twice daily for six days had no meaningful effect on the pharmacokinetics of alogliptin or metformin.</p>
<p>Specific pharmacokinetic drug interaction studies with KAZANO have not been performed, although such studies have been conducted with the individual components of KAZANO (alogliptin and metformin).</p>
<p><span class="Bold">Alogliptin</span></p>
<p><span class="Bold"><span class="Italics">In Vitro</span> Assessment of Drug Interactions</span></p>
<p><span class="Italics">In vitro</span> studies indicate that alogliptin is neither an inducer of CYP1A2, CYP2B6, CYP2C9, CYP2C19 and CYP3A4, nor an inhibitor of CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP3A4 and CYP2D6 at clinically relevant concentrations.</p>
<p><span class="Bold"><span class="Italics">In Vivo Assessment of Drug Interactions</span></span></p>
<p><span class="Bold"><span class="Underline">Effects of Alogliptin on the Pharmacokinetics of Other Drugs</span></span></p>
<p>In clinical studies, alogliptin did not meaningfully increase the systemic exposure to the following drugs that are metabolized by CYP isozymes or excreted unchanged in urine <span class="Italics">(Figure 1)</span>. No dose adjustment of alogliptin is recommended based on results of the described pharmacokinetic studies.</p>
<p><span class="Bold">Figure 1. Effect of Alogliptin on the Pharmacokinetic Exposure to Other Drugs</span></p>
<div class="Figure">
<a name="id595373"></a><img alt="Figure1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83cb7914-a683-47bb-a713-f2bc6a596bd2&amp;name=c953d30e-0172-491a-b227-36b1636b6ad2-03.jpg">
</div>
<p><span class="Sup">*</span>Warfarin was given once daily at a stable dose in the range of 1 mg to 10 mg. Alogliptin had no significant effect on the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (PT) or International Normalized Ratio (INR).</p>
<p><span class="Sup">**</span>Caffeine (1A2 substrate), tolbutamide (2C9 substrate), dextromethorphan (2D6 substrate), midazolam (3A4 substrate) and fexofenadine (P-gp substrate) were administered as a cocktail.</p>
<p><span class="Bold"><span class="Italics"><span class="Underline">Effects of Other Drugs on the Pharmacokinetics of Alogliptin</span></span></span></p>
<p>There are no clinically meaningful changes in the pharmacokinetics of alogliptin when alogliptin is administered concomitantly with the drugs described below <span class="Italics">(Figure 2)</span>.</p>
<p><span class="Bold">Figure 2. Effect of Other Drugs on the Pharmacokinetic Exposure of Alogliptin</span></p>
<div class="Figure">
<a name="id595483"></a><img alt="Figure2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83cb7914-a683-47bb-a713-f2bc6a596bd2&amp;name=c953d30e-0172-491a-b227-36b1636b6ad2-04.jpg">
</div>
<p><span class="Bold">Metformin Hydrochloride</span></p>
<p>Pharmacokinetic drug interaction studies have been performed on metformin <span class="Italics">(Tables 4 and 5)</span>.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_944c4d38-e576-4e88-bcca-17e7141514c9"></a><a name="section-11.3.6"></a><p></p>
<table width="100%">
<col width="22%">
<col width="18%">
<col width="18%">
<col width="20%">
<col width="22%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>All metformin and coadministered drugs were given as single doses</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">†</a></dt>
<dd>AUC = AUC<span class="Sub">0-∞</span>
</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">‡</a></dt>
<dd>Metformin hydrochloride extended-release tablets 500 mg</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">§</a></dt>
<dd>Ratio of arithmetic means</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">¶</a></dt>
<dd>At steady-state with topiramate 100 mg every 12 hours and metformin 500 mg every 12 hours; AUC = AUC<span class="Sub">0-12h</span>
</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="5" valign="top"><p class="First"><span class="Bold">Table 4. Effect of Coadministered Drug on Plasma Metformin Systemic Exposure</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Coadministered Drug</span></p></td>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="bottom">
<p class="First"><span class="Bold">Dose of </span></p>
<p><span class="Bold">Coadministered </span></p>
<p><span class="Bold">Drug</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a></p>
</td>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Dose of<br>Metformin HCl</span><a href="#footnote-5" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle">
<p class="First"><span class="Bold">Geometric Mean Ratio (ratio </span></p>
<p><span class="Bold">with/without coadministered drug)</span><br><span class="Bold">No effect = 1.00</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">AUC</span><a name="footnote-reference-6" href="#footnote-6" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">C<span class="Sub">max</span></span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First">No dosing adjustments required for the following: </p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Glyburide</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">5 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">500 mg<a name="footnote-reference-7" href="#footnote-7" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0.98<a name="footnote-reference-8" href="#footnote-8" class="Sup">§</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0.99<a href="#footnote-8" class="Sup">§</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Furosemide</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">40 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">850 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1.09<a href="#footnote-8" class="Sup">§</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1.22<a href="#footnote-8" class="Sup">§</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Nifedipine</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">10 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">850 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1.16</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1.21</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Propranolol</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">40 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">850 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0.90</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0.94</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Ibuprofen</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">400 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">850 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1.05<a href="#footnote-8" class="Sup">§</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1.07<a href="#footnote-8" class="Sup">§</a></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold">Cationic drugs eliminated by renal tubular secretion may reduce metformin elimination: use with caution </span><span class="Italics">[see<a href="#S5"> Warnings and Precautions (5) </a>and<a href="#S7"> Drug Interactions (7)</a>]</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Cimetidine</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">400 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">850 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1.40</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1.61</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold">Carbonic anhydrase inhibitors may cause <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>: use with caution </span><span class="Italics">[see<a href="#S5"> Warnings and Precautions (5) </a>and<a href="#S7"> Drug Interactions (7)</a>]</span></p></td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Topiramate</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">100 mg<a name="footnote-reference-9" href="#footnote-9" class="Sup">¶</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">500 mg<a href="#footnote-9" class="Sup">¶</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1.25<a href="#footnote-9" class="Sup">¶</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1.17</p></td>
</tr>
</tbody>
</table>
<table width="100%">
<col width="23%">
<col width="18%">
<col width="17%">
<col width="20%">
<col width="22%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-10" href="#footnote-reference-10">*</a></dt>
<dd>All metformin and coadministered drugs were given as single doses</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">†</a></dt>
<dd>AUC = AUC<span class="Sub">0-∞</span>
</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">‡</a></dt>
<dd>AUC<span class="Sub">0-24</span> hr reported</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">§</a></dt>
<dd>Ratio of arithmetic means, p-value of difference &lt;0.05</dd>
<dt><a name="footnote-14" href="#footnote-reference-14">¶</a></dt>
<dd>Ratio of arithmetic means</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="5" valign="top"><p class="First"><span class="Bold">Table 5. Effect of Metformin on Coadministered Drug Systemic Exposure</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Coadministered Drug</span></p></td>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="bottom">
<p class="First"><span class="Bold">Dose of </span></p>
<p><span class="Bold">Coadministered </span></p>
<p><span class="Bold">Drug</span><a name="footnote-reference-10" href="#footnote-10" class="Sup">*</a></p>
</td>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Dose of<br>Metformin HCl</span><a href="#footnote-10" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First"><span class="Bold">Geometric Mean Ratio (ratio with/without coadministered drug)</span><br><span class="Bold">No effect = 1.00</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">AUC</span><a name="footnote-reference-11" href="#footnote-11" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">C<span class="Sub">max</span></span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First">No dosing adjustments required for the following:</p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Glyburide</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">5 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">500 mg<a name="footnote-reference-12" href="#footnote-12" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0.78<a name="footnote-reference-13" href="#footnote-13" class="Sup">§</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0.63<a href="#footnote-13" class="Sup">§</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Furosemide</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">40 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">850 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0.87<a href="#footnote-13" class="Sup">§</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0.69<a href="#footnote-13" class="Sup">§</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Nifedipine</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">10 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">850 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1.10<a href="#footnote-12" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1.08</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Propranolol</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">40 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">850 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1.01<a href="#footnote-12" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0.94</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Ibuprofen</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">400 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">850 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0.97<a name="footnote-reference-14" href="#footnote-14" class="Sup">¶</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1.01<a href="#footnote-14" class="Sup">¶</a></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Cimetidine</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">400 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">850 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0.95<a href="#footnote-12" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1.01</p></td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13	NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Bold">Alogliptin and Metformin Hydrochloride</span></p>
<p>No carcinogenicity, mutagenicity or impairment of fertility studies have been conducted with KAZANO. The following data are based on findings in studies performed with alogliptin or metformin individually.</p>
<p><span class="Bold">Alogliptin</span></p>
<p>Rats were administered oral doses of 75, 400 and 800 mg/kg alogliptin for two years. No drug-related tumors were observed up to 75 mg/kg or approximately 32 times the maximum recommended clinical dose of 25 mg, based on AUC exposure. At higher doses (approximately 308 times the maximum recommended clinical dose of 25 mg), a combination of thyroid C-cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> and carcinomas increased in male but not female rats. No drug-related tumors were observed in mice after administration of 50, 150 or 300 mg/kg alogliptin for two years, or up to approximately 51 times the maximum recommended clinical dose of 25 mg, based on AUC exposure.</p>
<p>Alogliptin was not mutagenic or clastogenic, with and without metabolic activation, in the Ames test with <span class="Italics">S. typhimurium</span> and <span class="Italics">E. coli</span> or the cytogenetic assay in mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells. Alogliptin was negative in the <span class="Italics">in vivo</span> mouse micronucleus study.</p>
<p>In a fertility study in rats, alogliptin had no adverse effects on early embryonic development, mating or fertility, at doses up to 500 mg/kg, or approximately 172 times the clinical dose based on plasma drug exposure (AUC).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a7903719-284e-408f-bfa5-73fc83f2d8b7"></a><a name="section-12.1.1"></a><p></p>
<p class="First"><span class="Bold">Metformin Hydrochloride</span></p>
<p>Long-term carcinogenicity studies have been performed in rats (dosing duration of 104 weeks) and mice (dosing duration of 91 weeks) at doses up to and including 900 mg/kg and 1500 mg/kg, respectively. These doses are both approximately four times the maximum recommended human daily dose of 2000 mg based on body surface area comparisons. No evidence of carcinogenicity with metformin was found in either male or female mice. Similarly, there was no tumorigenic potential observed with metformin in male rats. There was an increased incidence of benign stromal uterine <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span> in female rats treated with 900 mg/kg.</p>
<p>There was no evidence of a mutagenic potential of metformin in the following <span class="Italics">in vitro</span> tests: Ames test (<span class="Italics">S. typhimurium</span>), gene mutation test (mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells) or chromosomal aberrations test (human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>). Results in the <span class="Italics">in vivo</span> mouse micronucleus test were also negative.</p>
<p>Fertility of male or female rats was unaffected by metformin when administered at doses as high as 600 mg/kg, which is approximately three times the maximum recommended human daily dose based on body surface area comparisons.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14	CLINICAL STUDIES</h1>
<p class="First">The coadministration of alogliptin and metformin has been studied in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> inadequately controlled on either diet and exercise alone, on metformin alone or metformin in combination with a thiazolidinedione.</p>
<p>There have been no clinical efficacy studies conducted with KAZANO; however, bioequivalence of KAZANO with coadministered alogliptin and metformin tablets was demonstrated, and efficacy of the combination of alogliptin and metformin has been demonstrated in three Phase 3 efficacy studies.</p>
<p>A total of 2095 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> were randomized in three double-blind, placebo- or active-controlled clinical safety and efficacy studies conducted to evaluate the effects of KAZANO on glycemic control. The racial distribution of patients exposed to study medication was 69.2% white, 16.3% Asian, 6.5% black and 8.0% other racial groups. The ethnic distribution was 24.3% Hispanic. Patients had an overall mean age of approximately 54.4 years (range 22 to 80 years). In patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, treatment with KAZANO produced clinically meaningful and statistically significant improvements in A1C versus comparator. As is typical for trials of agents to treat type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, the mean reduction in A1C with KAZANO appears to be related to the degree of A1C elevation at baseline.</p>
<p><span class="Bold">Alogliptin and Metformin Coadministration in Patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Inadequately Controlled on Diet and Exercise</span></p>
<p>In a 26-week, double-blind, placebo-controlled study, a total of 784 patients inadequately controlled on diet and exercise alone (mean baseline A1C = 8.4%) were randomized to one of seven treatment groups: placebo; metformin HCl 500 mg or metformin HCl 1000 mg twice daily, alogliptin 12.5 mg twice daily, or alogliptin 25 mg daily; alogliptin 12.5 mg in combination with metformin HCl 500 mg or metformin HCl 1000 mg twice daily. Both coadministration treatment arms (alogliptin 12.5 mg + metformin HCl 500 mg and alogliptin 12.5 mg + metformin HCl 1000 mg) resulted in significant improvements in A1C <span class="Italics">(Figure 3)</span> and FPG when compared with their respective individual alogliptin and metformin component regimens <span class="Italics">(Table 6)</span>. Coadministration treatment arms demonstrated improvements in two-hour postprandial glucose (PPG) compared to alogliptin alone or metformin alone <span class="Italics">(Table 6)</span>. A total of 12% of patients receiving alogliptin 12.5 mg + metformin HCl 500 mg, 3% of patients receiving alogliptin 12.5 mg + metformin HCl 1000 mg, 17% of patients receiving alogliptin 12.5 mg, 23% of patients receiving metformin HCl 500 mg, 11% of patients receiving metformin HCl 1000 mg and 39% of patients receiving placebo required glycemic rescue.</p>
<p>Improvements in A1C were not affected by gender, age, race or baseline BMI. The mean decrease in body weight was similar between metformin alone and alogliptin when coadministered with metformin. Lipid effects were neutral.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b251fdee-d0d1-409e-9295-798909754319"></a><a name="section-13.1"></a><p></p>
<table width="100%">
<col width="21%">
<col width="11%">
<col width="11%">
<col width="16%">
<col width="16%">
<col width="13%">
<col width="13%">
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-15" href="#footnote-reference-15">*</a></dt>
<dd>Intent-to-treat population using last observation on study prior to discontinuation of double-blind study medication or sulfonylurea rescue therapy for patients needing rescue</dd>
<dt><a name="footnote-16" href="#footnote-reference-16">†</a></dt>
<dd>Least squares means adjusted for treatment, geographic region and baseline value</dd>
<dt><a name="footnote-17" href="#footnote-reference-17">‡</a></dt>
<dd>p&lt;0.05 when compared to metformin and alogliptin alone</dd>
<dt><a name="footnote-18" href="#footnote-reference-18">§</a></dt>
<dd>Compared using logistic regression</dd>
<dt><a name="footnote-19" href="#footnote-reference-19">¶</a></dt>
<dd>Intent-to-treat population using data available at Week 26</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="7" valign="top"><p class="First"><span class="Bold">Table 6. Glycemic Parameters at Week 26 for Alogliptin and Metformin Alone and in Combination in Patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Placebo</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Alogliptin<br>12.5 mg <br>twice daily</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Metformin HCl <br>500 mg <br>twice daily</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Metformin HCl <br>1000 mg <br>twice daily</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Alogliptin <br>12.5 mg <br>+ Metformin HCl <br>500 mg <br>twice daily</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Alogliptin <br>12.5 mg <br>+ Metformin HCl <br>1000 mg <br>twice daily</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">A1C (%)</span><a name="footnote-reference-15" href="#footnote-15" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">N=102</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">N=104</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">N=103</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">N=108</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">N=102</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">N=111</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Change from baseline (adjusted mean<a name="footnote-reference-16" href="#footnote-16" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-1.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-1.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-1.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Difference from metformin (adjusted mean<a href="#footnote-16" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.6<a name="footnote-reference-17" href="#footnote-17" class="Sup">‡</a><br>(-0.9, -0.3)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.4<a href="#footnote-17" class="Sup">‡</a><br>(-0.7, -0.2)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Difference from alogliptin (adjusted mean<a href="#footnote-16" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">-0.7<a href="#footnote-17" class="Sup">‡</a></p>
<p>(-1.0, -0.4)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-1.0<a href="#footnote-17" class="Sup">‡</a><br>(-1.3, -0.7)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">% of Patients (n/N) achieving A1C &lt;7%<a name="footnote-reference-18" href="#footnote-18" class="Sup">§</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">4%<br>(4/102)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">20%<br>(21/104)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">27%<br>(28/103)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">34%<br>(37/108)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">47%<a href="#footnote-17" class="Sup">‡</a><br>(48/102)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">59%<a href="#footnote-17" class="Sup">‡</a><br>(66/111)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">FPG (mg/dL)</span><a href="#footnote-15" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">N=105</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">N=106</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">N=106</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">N=110</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">N=106</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">N=112</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">187</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">177</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">180</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">181</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">176</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">185</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Change from baseline <br>(adjusted mean<a href="#footnote-16" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-10</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-12</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-32</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-32</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-46</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Difference from metformin (adjusted mean<a href="#footnote-16" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-20<a href="#footnote-17" class="Sup">‡</a><br>(-33, -8)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">-14<a href="#footnote-17" class="Sup">‡</a></p>
<p>(-26, -2)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Difference from alogliptin (adjusted mean<a href="#footnote-16" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-22<a href="#footnote-17" class="Sup">‡</a><br>(-35, -10)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-36<a href="#footnote-17" class="Sup">‡</a><br>(-49, -24)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">2-Hour PPG (mg/dL)</span><a name="footnote-reference-19" href="#footnote-19" class="Sup">¶</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">N=26</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">N=34</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">N=28</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">N=37</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">N=31</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">N=37</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">263</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">272</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">247</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">266</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">261</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">268</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Change from baseline <br>(adjusted mean<a href="#footnote-16" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-21</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-43</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-49</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-54</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-68</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-86<a href="#footnote-17" class="Sup">‡</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Difference from metformin (adjusted mean<a href="#footnote-16" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-19<br>(-49, 11)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-32<a href="#footnote-17" class="Sup">‡</a><br>(-58, -5)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Difference from alogliptin (adjusted mean<a href="#footnote-16" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">-25</p>
<p>(-53, 3)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">-43<a href="#footnote-17" class="Sup">‡</a></p>
<p>(-70, -16)</p>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_21508e62-aa1a-4b19-b2ba-66588f8325c2"></a><a name="section-13.2"></a><p></p>
<p class="First"><span class="Bold">Figure 3. Change from Baseline A1C at Week 26 with Alogliptin and Metformin Alone and Alogliptin in Combination with Metformin</span></p>
<div class="Figure">
<a name="id63992830"></a><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83cb7914-a683-47bb-a713-f2bc6a596bd2&amp;name=c953d30e-0172-491a-b227-36b1636b6ad2-05.jpg">
</div>
<p><span class="Bold">Alogliptin and Metformin Coadministration in Patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Inadequately Controlled on Metformin Alone</span></p>
<p>In a 26-week, double-blind, placebo-controlled study, a total of 527 patients already on metformin (mean baseline A1C = 8%) were randomized to receive alogliptin 12.5 mg, alogliptin 25 mg, or placebo once daily. Patients were maintained on a stable dose of metformin HCl (median daily dose = 1700 mg) during the treatment period. Alogliptin 25 mg in combination with metformin resulted in statistically significant improvements from baseline in A1C and FPG at Week 26, when compared to placebo <span class="Italics">(Table 7)</span>. A total of 8% of patients receiving alogliptin 25 mg and 24% of patients receiving placebo required glycemic rescue. Improvements in A1C were not affected by gender, age, race, baseline BMI or baseline metformin dose.</p>
<p>The mean decrease in body weight was similar between alogliptin 25 mg and placebo when given in combination with metformin. Lipid effects were also neutral.</p>
<table width="100%">
<col width="41%">
<col width="29%">
<col width="29%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-20" href="#footnote-reference-20">*</a></dt>
<dd>Intent-to-treat population using last observation on study.</dd>
<dt><a name="footnote-21" href="#footnote-reference-21">†</a></dt>
<dd>Least squares means adjusted for treatment, baseline value, geographic region and baseline metformin dose.</dd>
<dt><a name="footnote-22" href="#footnote-reference-22">‡</a></dt>
<dd>p&lt;0.001 compared to placebo.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="3" valign="top"><p class="First"><span class="Bold">Table 7. Glycemic Parameters at Week 26 in a Placebo-Controlled Study of Alogliptin as Add-on Therapy to Metformin</span><a name="footnote-reference-20" href="#footnote-20" class="Sup">*</a></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Alogliptin 25 mg <br>+ Metformin</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Placebo <br>+ Metformin</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">A1C (%)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">N=203</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">N=103</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">7.9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Change from baseline <br>  (adjusted mean<a name="footnote-reference-21" href="#footnote-21" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Difference from placebo <br>  (adjusted mean<a href="#footnote-21" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.5<a name="footnote-reference-22" href="#footnote-22" class="Sup">‡</a><span class="Italics"></span>(-0.7, -0.3)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  % of patients (n/N) achieving A1C ≤7%<a href="#footnote-22" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">44% (92/207)<a href="#footnote-22" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">18% (19/104)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">N=204</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">N=104</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">172</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">180</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Change from baseline <br>  (adjusted mean<a href="#footnote-21" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-17</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Difference from placebo <br>  (adjusted mean<a href="#footnote-21" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-17<a href="#footnote-22" class="Sup">‡</a> (-26, -9)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7dfde9be-f5f7-4e3e-90c1-e7836cbb49c1"></a><a name="section-13.3"></a><p></p>
<p class="First"><span class="Bold">Alogliptin Add-On Therapy in Patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Inadequately Controlled on the Combination of Metformin and Pioglitazone</span></p>
<p>In a 52-week, active-comparator study, a total of 803 patients inadequately controlled (mean baseline A1C = 8.2%) on a current regimen of pioglitazone 30 mg and metformin were randomized to either receive the addition of once-daily alogliptin 25 mg or the titration of pioglitazone 30 mg to 45 mg following a four-week single-blind, placebo run-in period. Patients were maintained on a stable dose of metformin HCl (median daily dose = 1700 mg). Patients who failed to meet prespecified hyperglycemic goals during the 52-week treatment period received glycemic rescue therapy.</p>
<p>In combination with pioglitazone and metformin, alogliptin 25 mg was shown to be statistically superior in lowering A1C and FPG compared with the titration of pioglitazone from 30 to 45 mg at Week 26 and at Week 52 <span class="Italics">(Table 8)</span>. A total of 11% of patients in the alogliptin 25 mg in combination with pioglitazone 30 mg and metformin treatment group and 22% of patients in the up titration of pioglitazone in combination with metformin treatment group required glycemic rescue. Improvements in A1C were not affected by gender, age, race or baseline BMI. </p>
<p>The mean increase in body weight was similar in both treatment arms. Lipid effects were neutral.</p>
<table width="100%">
<col width="40%">
<col width="30%">
<col width="30%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-23" href="#footnote-reference-23">*</a></dt>
<dd>Intent-to-treat population using last observation on study</dd>
<dt><a name="footnote-24" href="#footnote-reference-24">†</a></dt>
<dd>Least squares means adjusted for treatment, baseline value, geographic region, and baseline metformin dose</dd>
<dt><a name="footnote-25" href="#footnote-reference-25">‡</a></dt>
<dd>Non-inferior and statistically superior to metformin plus pioglitazone at the 0.025 one-sided significance level</dd>
<dt><a name="footnote-26" href="#footnote-reference-26">§</a></dt>
<dd>p&lt;0.001 compared to pioglitazone 45 mg + metformin</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="3" valign="middle"><p class="First"><span class="Bold">Table 8. Glycemic Parameters at Week 52 in an Active-Controlled Study of Alogliptin as Add-On Combination Therapy to Metformin and Pioglitazone</span><a name="footnote-reference-23" href="#footnote-23" class="Sup">*</a></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Alogliptin 25 mg <br>+ Pioglitazone 30 mg <br>+ Metformin</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">Pioglitazone 45 mg <br>+ Metformin</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">A1C (%)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">N=397</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">N=394</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Change from baseline <br>(adjusted mean<a name="footnote-reference-24" href="#footnote-24" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Difference from <br>pioglitazone 45 mg + metformin<a href="#footnote-23" class="Sup">*</a><br>(adjusted mean<a href="#footnote-24" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.4<a name="footnote-reference-25" href="#footnote-25" class="Sup">‡</a> (-0.5, -0.3)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">% of Patients (n/N) <br>achieving A1C ≤7%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">33% (134/404)<a name="footnote-reference-26" href="#footnote-26" class="Sup">§</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">21% (85/399)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">FPG (mg/dL)</span><a href="#footnote-25" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">N=399</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">N=396</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">162</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">162</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Change from baseline <br>(adjusted mean<a href="#footnote-24" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-15</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-4</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Difference from <br>pioglitazone 45 mg + metformin <br>(adjusted mean<a href="#footnote-24" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-11<a href="#footnote-26" class="Sup">§</a> (-16, -6)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">KAZANO tablets are available in the following strengths and packages:</p>
<p>12.5 mg/500 mg tablet: <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, oblong, film-coated tablets with "12.5/500" debossed on one side and "322M" debossed on the other side, available in:</p>
<table width="100%">
<col width="49%">
<col width="51%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"><p class="First">NDC 64764-335-60</p></td>
<td class="Toprule" valign="top"><p class="First">Bottles of 60 tablets </p></td>
</tr>
<tr>
<td valign="top"><p class="First">NDC 64764-335-80</p></td>
<td valign="top"><p class="First">Bottles of 180 tablets</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">NDC 64764-335-77</p></td>
<td class="Botrule" valign="top"><p class="First">Bottles of 500 tablets</p></td>
</tr>
</tbody>
</table>
<p>12.5 mg/1000 mg tablet: <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, oblong, film-coated tablets with "12.5/1000" debossed on one side and "322M" debossed on the other side, available in:</p>
<table width="100%">
<col width="49%">
<col width="51%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"><p class="First">NDC 64764-337-60</p></td>
<td class="Toprule" valign="top"><p class="First">Bottles of 60 tablets </p></td>
</tr>
<tr>
<td valign="top"><p class="First">NDC 64764-337-80</p></td>
<td valign="top"><p class="First">Bottles of 180 tablets</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">NDC 64764-337-77</p></td>
<td class="Botrule" valign="top"><p class="First">Bottles of 500 tablets</p></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="ID_dded451d-423c-474d-a801-0dcbfb6c4fb7"></a><a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">Storage</span></p>
<p>Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Keep container tightly closed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17	PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-Approved Patient Labeling (Medication Guide).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.1"></a><a name="section-15.1"></a><p></p>
<h2>17.1	Instructions</h2>
<dl>
<dt>•</dt>
<dd>Inform patients of the potential risks and benefits of KAZANO.</dd>
<dt>•</dt>
<dd>The risks of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, its symptoms, and conditions that predispose to its development, as noted in <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a></span>, should be explained to patients. Patients should be advised to discontinue KAZANO immediately and to promptly notify their health practitioner if unexplained <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, unusual <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> or other nonspecific symptoms occur. Once a patient is stabilized on any dose level of KAZANO, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>, which are common during initiation of metformin therapy, are unlikely to recur. Later occurrence of <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> could be due to <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or other serious disease.</dd>
<dt>•</dt>
<dd>Patients should be informed that <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span> has been reported during use of alogliptin. Patients should be informed that persistent, severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, sometimes radiating to the back, which may or may not be accompanied by <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, is the hallmark symptom of <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span>. Patients should be instructed to promptly discontinue KAZANO and contact their physician if persistent severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> occurs.</dd>
<dt>•</dt>
<dd>Patients should be informed that <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> have been reported during use of alogliptin and metformin. If symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> (including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, tongue and throat that may cause difficulty in breathing or swallowing) occur, patients should be instructed to discontinue KAZANO and seek medical advice promptly.</dd>
<dt>•</dt>
<dd>Patients should be informed that postmarketing reports of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, sometimes fatal, have been reported during use of alogliptin. If signs or symptoms of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> occur, patients should be instructed to discontinue KAZANO and seek medical advice promptly.</dd>
<dt>•</dt>
<dd>Patients should be informed about the importance of regular testing of renal function and hematological parameters when receiving treatment with KAZANO.</dd>
<dt>•</dt>
<dd>Patients should be counseled against excessive alcohol intake, either acute or chronic, while receiving KAZANO.</dd>
<dt>•</dt>
<dd>Inform patients that <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> can occur, particularly when an insulin secretagogue or insulin is used in combination with KAZANO. Explain the risks, symptoms and appropriate management of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</dd>
<dt>•</dt>
<dd>Inform patients that severe and disabling <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span> may occur with this class of drugs. The time to onset of symptoms can range from one day to years. Instruct patients to seek medical advice if severe <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span> occurs. </dd>
<dt>•</dt>
<dd>Instruct patients to take KAZANO only as prescribed twice daily. KAZANO should be taken with food. If a dose is missed, advise patients not to double their next dose.</dd>
<dt>•</dt>
<dd>Patients should be informed that the tablets must never be split.</dd>
</dl>
<p class="First">Instruct patients to read the Medication Guide before starting KAZANO therapy and to reread each time the prescription is refilled. Instruct patients to inform their healthcare provider if an unusual symptom develops or if a symptom persists or worsens.</p>
<p>Revised: August 2015</p>
<p>ALM143P R4</p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="ID_3630b2a8-939e-4db4-97bd-79ac43dc4de8"></a><a name="section-16"></a><p></p>
<h1>MEDICATION GUIDE  </h1>
<p class="First"><span class="Bold">KAZANO (Kah-ZAHN-oh)</span></p>
<p><span class="Bold">(alogliptin and metformin HCl)</span></p>
<p><span class="Bold">tablets</span></p>
<p>Read this Medication Guide carefully before you start taking KAZANO and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or treatment. If you have any questions about KAZANO, ask your doctor or pharmacist.</p>
<p><span class="Bold">What is the most important information I should know about KAZANO?</span></p>
<p><span class="Bold">KAZANO can cause serious side effects, including:</span></p>
<p><span class="Bold">1. <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>. </span>Metformin, one of the medicines in KAZANO, can cause a rare but serious condition called <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> (a buildup of an acid in the blood) that can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> is a medical emergency and must be treated in the hospital.</p>
<p><span class="Bold">Stop taking KAZANO and call your doctor right away if you get any of the following symptoms of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>:</span></p>
<table width="100%">
<col width="48%">
<col width="52%">
<tbody class="Headless">
<tr class="First">
<td valign="top"><dl>
<dt>•</dt>
<dd>feel very weak or tired</dd>
</dl></td>
<td valign="top"><dl>
<dt>•</dt>
<dd>have unusual (not normal) <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span></dd>
</dl></td>
</tr>
<tr>
<td valign="top"><dl>
<dt>•</dt>
<dd>have trouble breathing</dd>
</dl></td>
<td valign="top"><dl>
<dt>•</dt>
<dd>have unusual <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> or sleep longer than usual</dd>
</dl></td>
</tr>
<tr>
<td valign="top"><dl>
<dt>•</dt>
<dd>have unexplained stomach or intestinal problems with <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>•</dt>
<dd>feel <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, especially in your arms and legs</dd>
</dl></td>
</tr>
<tr class="Last">
<td valign="top"><dl>
<dt>•</dt>
<dd>feel dizzy or lightheaded</dd>
</dl></td>
<td valign="top"><dl>
<dt>•</dt>
<dd>have a slow or irregular heartbeat</dd>
</dl></td>
</tr>
</tbody>
</table>
<p><span class="Bold">You have a higher chance for getting <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> with KAZANO if you:</span></p>
<dl>
<dt>•</dt>
<dd>have kidney problems. People whose kidneys are not working properly should not take KAZANO</dd>
<dt>•</dt>
<dd>have liver problems</dd>
<dt>•</dt>
<dd>have <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> that requires treatment with medicines</dd>
<dt>•</dt>
<dd>drink a lot of alcohol (very often or short-term “binge? drinking)</dd>
<dt>•</dt>
<dd>get dehydrated (lose a large amount of body fluids). This can happen if you are sick with a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span> can also happen when you sweat a lot with activity or exercise and do not drink enough fluids</dd>
<dt>•</dt>
<dd>have certain x-ray tests with injectable dyes or contrast agents</dd>
<dt>•</dt>
<dd>have surgery</dd>
<dt>•</dt>
<dd>have a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></dd>
</dl>
<p><span class="Bold">2. <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> of the pancreas (<span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>). </span>Alogliptin, one of the medicines in KAZANO, may cause <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, which may be severe. Certain medical conditions make you more likely to get <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</p>
<p><span class="Bold">Before you start taking KAZANO:</span></p>
<p>Tell your doctor if you have ever had:</p>
<table width="100%">
<col width="27%">
<col width="44%">
<col width="29%">
<tbody class="Headless">
<tr class="First">
<td valign="top"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>•</dt>
<dd>stones in your gallbladder (<span class="product-label-link" type="condition" conceptid="196456" conceptname="Gallstone">gallstones</span>)</dd>
</dl></td>
<td valign="top"><dl>
<dt>•</dt>
<dd>a history of <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span></dd>
</dl></td>
</tr>
<tr class="Last">
<td valign="top"><dl>
<dt>•</dt>
<dd>kidney problems</dd>
</dl></td>
<td valign="top"><dl>
<dt>•</dt>
<dd>liver problems</dd>
</dl></td>
<td valign="top"></td>
</tr>
</tbody>
</table>
<p>Stop taking KAZANO and call your doctor right away if you have <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your stomach area (abdomen) that is severe and will not go away. The <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> may be felt going from your abdomen through to your back. The <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> may happen with or without <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. These may be symptoms of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</p>
<p><span class="Bold">What is KAZANO?</span></p>
<dl>
<dt>•</dt>
<dd>KAZANO contains 2 prescription <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines, alogliptin (NESINA) and metformin hydrochloride.</dd>
<dt>•</dt>
<dd>KAZANO is a prescription medicine used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</dd>
<dt>•</dt>
<dd>KAZANO is not for people with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</dd>
<dt>•</dt>
<dd>KAZANO is not for people with <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span> (increased <span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">ketones</span> in blood or urine).</dd>
</dl>
<p>It is not known if KAZANO is safe and effective in children under the age of 18.</p>
<p><span class="Bold">Who should not take KAZANO?</span></p>
<p><span class="Bold">Do not take KAZANO if you:</span></p>
<dl>
<dt>•</dt>
<dd>have kidney problems</dd>
<dt>•</dt>
<dd>have a condition called <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> or have had <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span> (increased <span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">ketones</span> in your blood or urine)</dd>
<dt>•</dt>
<dd>are going to get an injection of dye or contrast agents for an x-ray procedure, KAZANO will need to be stopped for a short time. Talk to your doctor about when you should stop KAZANO and when you should start KAZANO again</dd>
<dt>•</dt>
<dd>are allergic to alogliptin (NESINA) or metformin or any of the ingredients in KAZANO or have had a serious allergic (<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>) reaction to alogliptin or metformin. See the end of this Medication Guide for a complete list of the ingredients in KAZANO</dd>
<dt> </dt>
<dd>Symptoms of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to KAZANO may include:</dd>
</dl>
<table width="100%">
<col width="57%">
<col width="43%">
<tbody class="Headless">
<tr class="First">
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, lips, throat and other areas on your skin</dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd>difficulty with swallowing or breathing</dd>
</dl></td>
</tr>
<tr class="Last">
<td valign="top"><dl>
<dt>o</dt>
<dd>raised, red areas on your skin (<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>)</dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, flaking or <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span></dd>
</dl></td>
</tr>
</tbody>
</table>
<dl>
<dt> </dt>
<dd>If you have any of these symptoms, stop taking KAZANO and contact your doctor right away or go to the nearest hospital emergency room.</dd>
</dl>
<p><span class="Bold">What should I tell my doctor before and during treatment with KAZANO?</span></p>
<p>Before you take KAZANO, tell your doctor if you:</p>
<dl>
<dt>•</dt>
<dd>have or have had <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of your pancreas (<span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>)</dd>
<dt>•</dt>
<dd>have kidney or liver problems </dd>
<dt>•</dt>
<dd>have heart problems, including <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span></dd>
<dt>•</dt>
<dd>are older than 80 years, you should not take KAZANO unless your kidneys have been checked and they are normal</dd>
<dt>•</dt>
<dd>drink alcohol very often or drink a lot of alcohol in short-term “binge? drinking</dd>
<dt>•</dt>
<dd>have other medical conditions</dd>
<dt>•</dt>
<dd>are pregnant or plan to become pregnant. It is not known if KAZANO will harm your unborn baby. Talk with your doctor about the best way to control your blood sugar while you are pregnant or if you plan to become pregnant</dd>
<dt>•</dt>
<dd>are breastfeeding or plan to breastfeed. It is not known whether KAZANO passes into your breast milk. Talk with your doctor about the best way to feed your baby if you are taking KAZANO</dd>
</dl>
<p><span class="Bold">Tell your doctor about all the medicines you take, </span>including prescription and over-the-counter medicines, vitamins and herbal supplements. Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist before you start any new medicine.</p>
<p>KAZANO may affect the way other medicines work, and other medicines may affect how KAZANO works. Contact your doctor before you start or stop other types of medicines.</p>
<p><span class="Bold">How should I take KAZANO?</span></p>
<dl>
<dt>•</dt>
<dd>Take KAZANO exactly as your doctor tells you to take it.</dd>
<dt>•</dt>
<dd>Take KAZANO 2 times each day.</dd>
<dt>•</dt>
<dd>Take KAZANO with food to lower your chances of having an <span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span>. </dd>
<dt>•</dt>
<dd>Do not break or cut KAZANO tablets before swallowing.</dd>
<dt>•</dt>
<dd>Your doctor may need to change your dose of KAZANO to control your blood glucose. Do not change your dose unless told to do so by your doctor.</dd>
<dt>•</dt>
<dd>If you miss a dose, take it as soon as you remember. If you do not remember until it is time for your next dose, skip the missed dose, and take the next dose at your regular schedule. Do not take 2 doses of KAZANO at the same time.</dd>
<dt>•</dt>
<dd>If you take too much KAZANO, call your doctor or go to the nearest hospital emergency room right away.</dd>
<dt>•</dt>
<dd>If your body is under stress, such as from <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span> or surgery, the dose of your <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines may need to be changed. Call your doctor right away. </dd>
<dt>•</dt>
<dd>Stay on your diet and exercise programs and check your blood sugar as your doctor tells you to.</dd>
<dt>•</dt>
<dd>Your doctor may do certain blood tests before you start KAZANO and during treatment as needed. Your doctor may ask you to stop taking KAZANO based on the results of your blood tests due to how well your kidneys are working. </dd>
<dt>•</dt>
<dd>Your doctor will check your <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> with regular blood tests, including your blood sugar levels and your hemoglobin A1C.</dd>
</dl>
<p><span class="Bold">What are the possible side effects of KAZANO?</span></p>
<p><span class="Bold">KAZANO can cause serious side effects, including:</span></p>
<p>See <span class="Bold">“What is the most important information I should know about KAZANO??</span></p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Allergic (<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>) reactions,</span> such as:</dd>
</dl>
<table width="100%">
<col width="50%">
<col width="50%">
<tbody class="Headless">
<tr class="First">
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, lips, throat and other areas on your skin</dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd>difficulty swallowing or breathing</dd>
</dl></td>
</tr>
<tr class="Last">
<td valign="top"><dl>
<dt>o</dt>
<dd>raised, red areas on your skin (<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>)</dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, flaking or <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span></dd>
</dl></td>
</tr>
</tbody>
</table>
<dl>
<dt> </dt>
<dd>If you have these symptoms, stop taking KAZANO and contact your doctor right away.</dd>
</dl>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Liver problems. </span>Call your doctor right away if you have symptoms, such as:</dd>
</dl>
<table width="100%">
<col width="25%">
<col width="22%">
<col width="53%">
<tbody class="Headless">
<tr class="First">
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd>unusual or unexplained <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></dd>
</dl></td>
</tr>
<tr class="Last">
<td valign="top"><dl>
<dt>o</dt>
<dd>loss of appetite</dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd>dark urine</dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd>yellowing of your skin or the whites of your eyes</dd>
</dl></td>
</tr>
</tbody>
</table>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>). </span>If you take KAZANO with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin, your risk of getting low blood sugar is higher. The dose of your sulfonylurea medicine or insulin may need to be lowered while you take KAZANO. If you have symptoms of low blood sugar, you should check your blood sugar and treat if low, and then call your doctor. Signs and symptoms of low blood sugar may include:</dd>
</dl>
<table width="100%">
<col width="19%">
<col width="20%">
<col width="21%">
<col width="20%">
<col width="19%">
<tbody class="Headless">
<tr class="First">
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> or <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">feeling jittery</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4205415" conceptname="Hungry">hunger</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd>change in mood</dd>
</dl></td>
</tr>
<tr class="Last">
<td valign="top"><dl>
<dt>o</dt>
<dd>fast heartbeat</dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd>change in vision</dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></dd>
</dl></td>
<td valign="top"></td>
</tr>
</tbody>
</table>
<dl>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Joint pain</span>.</span> Some people who take medicines called DPP-4 inhibitors, one of the medicines in KAZANO, may develop <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span> that can be severe. Call your doctor if you have severe <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>. </dd>
</dl>
<p>The most common side effects of KAZANO include:</p>
<table width="100%">
<col width="33%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First Toprule">
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>-like symptoms (<span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>)</dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd>stuffy or <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span> and <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></dd>
</dl></td>
</tr>
<tr>
<td valign="top"><dl>
<dt>o</dt>
<dd>increase in blood pressure</dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span></dd>
</dl></td>
</tr>
<tr class="Botrule Last">
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span></dd>
</dl></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
</tbody>
</table>
<p>Taking KAZANO with food can help lessen the common stomach side effects of metformin that usually happen at the beginning of treatment. If you have unexplained stomach problems, tell your doctor. Stomach problems that start later, during treatment, may be a sign of something more serious. </p>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of KAZANO. For more information, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store KAZANO?</span></p>
<dl>
<dt>•</dt>
<dd>Store KAZANO at room temperature between 68°F to 77°F (20°C to 25°C).</dd>
<dt>•</dt>
<dd>Keep the container of KAZANO tightly closed.</dd>
</dl>
<p><span class="Bold">Keep KAZANO and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of KAZANO</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in the Medication Guide. Do not take KAZANO for a condition for which it was not prescribed. Do not give KAZANO to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about KAZANO. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about KAZANO that is written for health professionals.</p>
<p>For more information go to www.kazano.com or call 1-877-TAKEDA-7 (1-877-825-3327).</p>
<p><span class="Bold">What are the ingredients in KAZANO?</span></p>
<p><span class="Bold">Active ingredients:</span> alogliptin and metformin hydrochloride</p>
<p><span class="Bold">Inactive ingredients:</span> mannitol, microcrystalline cellulose, povidone, crospovidone and magnesium stearate; the tablets are film-coated with hypromellose 2910, talc, titanium dioxide and ferric oxide yellow.</p>
<p>Distributed by:<br><span class="Bold">Takeda Pharmaceuticals America, Inc</span>.<br>Deerfield, IL 60015</p>
<p>KAZANO and NESINA are trademarks of Takeda Pharmaceutical Company Limited registered with the U.S. Patent and Trademark Office and are used under license by Takeda Pharmaceuticals America, Inc.</p>
<p>©2013 - 2015 Takeda Pharmaceuticals America, Inc.</p>
<p>ALM143P R4</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.                                           8/2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_45f543d7-e613-43d1-9d83-66bdc536a0c3"></a><a name="section-17"></a><p></p>
<h1>
<span class="Bold">PRINCIPAL DISPLAY PANEL – 12.5 MG/500 MG</span> </h1>
<p class="First"><span class="Bold">NDC </span>64764-<span class="Bold">335-</span>60</p>
<p><span class="Bold">Kazano</span></p>
<p><span class="Bold">(alogliptin and</span><br><span class="Bold">metformin HCl) tablets</span></p>
<p><span class="Bold">12.5* mg/500 mg</span></p>
<p><span class="Bold">Dispense with</span><br><span class="Bold">Medication Guide</span></p>
<p><span class="Bold">60 Tablets</span></p>
<p><span class="Italics">Takeda logo</span></p>
<p>Rx Only</p>
<p><a name="id9017608"></a><img alt="Kazano12.5-500BottleLabel" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83cb7914-a683-47bb-a713-f2bc6a596bd2&amp;name=c953d30e-0172-491a-b227-36b1636b6ad2-06.jpg">]</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_7ae686be-af83-4d96-a0ae-50ad2e5aab8a"></a><a name="section-18"></a><p></p>
<h1> </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL – 12.5 MG/500 MG</span></p>
<p><span class="Bold">NDC </span>64764-<span class="Bold">337-</span>60</p>
<p><span class="Bold">Kazano</span></p>
<p><span class="Bold">(alogliptin and</span><br><span class="Bold">metformin HCl) tablets</span></p>
<p><span class="Bold">12.5* mg/500 mg</span></p>
<p><span class="Bold">Dispense with</span><br><span class="Bold">Medication Guide</span></p>
<p><span class="Bold">60 Tablets</span></p>
<p><span class="Italics">Takeda logo</span></p>
<p>Rx Only</p>
<div class="Figure">
<a name="id-200023429"></a><img alt="Kazano12.5-1000BottleLabel" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83cb7914-a683-47bb-a713-f2bc6a596bd2&amp;name=c953d30e-0172-491a-b227-36b1636b6ad2-07.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>KAZANO 		
					</strong><br><span class="contentTableReg">alogliptin and metformin hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64764-335</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALOGLIPTIN BENZOATE</strong> (Alogliptin) </td>
<td class="formItem">Alogliptin</td>
<td class="formItem">12.5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Metformin hydrochloride</strong> (Metformin) </td>
<td class="formItem">Metformin hydrochloride</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>crospovidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide yellow</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (<span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (oblong) </td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">12;5;500;322M</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64764-335-60</td>
<td class="formItem">60  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:64764-335-80</td>
<td class="formItem">180  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:64764-335-77</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:64764-335-01</td>
<td class="formItem">4  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">14  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA203414</td>
<td class="formItem">01/25/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>KAZANO 		
					</strong><br><span class="contentTableReg">alogliptin and metformin hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64764-337</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALOGLIPTIN BENZOATE</strong> (Alogliptin) </td>
<td class="formItem">Alogliptin</td>
<td class="formItem">12.5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Metformin hydrochloride</strong> (Metformin) </td>
<td class="formItem">Metformin hydrochloride</td>
<td class="formItem">1000 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>crospovidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide yellow</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (<span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (oblong) </td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">12;5;1000;322M</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64764-337-60</td>
<td class="formItem">60  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:64764-337-80</td>
<td class="formItem">180  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:64764-337-77</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:64764-337-01</td>
<td class="formItem">4  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">14  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA203414</td>
<td class="formItem">01/25/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Takeda Pharmaceuticals America, Inc.
							(830134016)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7c165c93-12f6-4d88-b308-0625d7c3134d</div>
<div>Set id: 83cb7914-a683-47bb-a713-f2bc6a596bd2</div>
<div>Version: 5</div>
<div>Effective Time: 20150831</div>
</div>
</div> <div class="DistributorName">Takeda Pharmaceuticals America, Inc.</div></p>
</body></html>
